Skip to main content
Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Proteomic profiling of small extracellular vesicles from bovine nucleus pulposus cells

  • Ankita Samanta,

    Roles Data curation, Writing – original draft

    Affiliation Department of Biology, Clarkson University, Potsdam, New York, United States of America

  • Mi-Jeong Yoo,

    Roles Data curation, Writing – original draft

    Affiliation Department of Biology, Clarkson University, Potsdam, New York, United States of America

  • Jin Koh,

    Roles Data curation, Writing – original draft

    Affiliation The Interdisciplinary Center for Biotechnology Research, University of Florida, Gainesville, Florida, United States of America

  • Sina Charlotte Lufkin,

    Roles Data curation, Visualization, Writing – review & editing

    Affiliation Department of Biology, Clarkson University, Potsdam, New York, United States of America

  • Thomas Lufkin,

    Roles Conceptualization, Funding acquisition, Writing – original draft

    Affiliation Department of Biology, Clarkson University, Potsdam, New York, United States of America

  • Petra Kraus

    Roles Conceptualization, Data curation, Funding acquisition, Supervision, Writing – original draft

    pkraus@clarkson.edu

    Affiliation Department of Biology, Clarkson University, Potsdam, New York, United States of America

Abstract

Small extracellular vesicles (small EV) are a conserved means of communication across the domains of life and lately gained more interest in mammalian non-cancerous work as non-cellular, biological therapeutic with encouraging results in recent studies of chronic degenerative diseases. The nucleus pulposus (NP) is the avascular and aneural center of an intervertebral disc (IVD), home to unique niche conditions and affected in IVD degeneration. We investigated autologous and mesenchymal stem cell (MSC) small EVs for their potential to contribute to cell and tissue homeostasis in the NP niche via mass spectrometric proteome and functional enrichment analysis using adult and fetal donors. We compared these findings to published small EV databases and MSC small EV data. We propose several mechanisms associated with NP small EVs: Membrane receptor trafficking to modify signal responses promoting niche homeostasis; Redox and energy homeostasis via metabolic enzymes delivery; Cell homeostasis via proteasome delivery and immunomodulation beyond an association with a serum protein corona. The proteome signature of small EVs generated by NP parent cells is similar to previously published small EV data, yet with a focus on supplementing anaerobic metabolism and redox balance while contributing to the maintenance of an aneural and avascular microniche.

Introduction

Lower back and neck pain present global health issues as they are significant causes of disability worldwide. It is the most frequent cause of worker’s compensation, lost working time, and decreased productivity and as such associated with a large socioeconomic burden [1,2]. Even if the etiology of most cases of back pain remains unknown, intervertebral disc degeneration (IVDD) is one of the most common factors [3,4]. IVDD principally impacts the intervertebral disc (IVD), resulting in structural modifications and functional impairments within the spinal column [57]. Addressing this complex and multidimensional illness with conventional approaches hampers clinical success. Therefore identifying factors that promote cell and tissue homeostasis prior to disc degeneration remains important [6,8].

The IVD is made up of a central nucleus pulposus (NP) surrounded by an inner and outer annulus fibrosus (AF), which is present in between the cartilaginous endplates (CEPs) (Fig 1A) [917]. The AF is mostly made up of collagen type I. Cells of the outer AF appear elongated, thin, and parallel to the collagen lamellae, while the inner AF looks fibrocartilaginous [10,13,14,1821]. The NP is of great functional importance and by volume the largest tissue type in the IVD. The NP has a relatively loose collagen network, is highly hydrated, and exhibits hydrostatic behavior under load when non-degenerate [6,10,14,18]. Proteoglycans (PG), in particular aggrecan (Acan) with its high anionic glycosaminoglycan (GAG) content, specifically chondroitin sulfate and keratan sulfate, comprise 5–15% of the weight of wet tissue. Their charges ensure the swelling pressure to maintain disc height and turgor under compressive load by attracting water molecules into the disc [10,19,22,23]. One of the earliest changes in IVDD is PG-loss and consequentially reduced water retention, resulting in decreased disc height and flexibility [10]. NP cells originate from the notochord (NC), a transient embryonic structure [13,24,25]. In the mature NP, unlike most tissues, few cells are embedded in a vast amount of extracellular matrix (ECM) [14,18]. In some species like rodents, and pigs NC cells are retained into mature adulthood where they continue to generate PGs and collagen [13,26,27]. In human and bovine IVDs, these NC cells are replaced by chondrocyte-like cells around the age of ten years [20,25,2837]. Similar to the bovine model, the adult human NP has a low cell density, with cells occupying less than 0.5% of the tissue volume [38]. With aging, the density of active NP cells declines further, presumably due to niche conditions [3941]. In general, bovine coccygeal IVDs are considered similar to healthy human IVDs [4245]. This makes the bovine IVD a suitable model to study cell homeostasis in the adult. Only recently, more information has become available on the proteome and transcriptome of healthy or degenerated IVDs from various species [4655] and more potential biomarkers defining NP and AF cells joined those previously established on the transcriptome level [47,52,56,57]. Contributions to this data would refine a characterization of the heterogeneous NP cell population and further define hallmarks to maintain or restore IVD tissue.

thumbnail
Fig 1. The intervertebral disc (IVD) and the generation of small extracellular vesicles.

A) Schematic representation of an IVD with a central nucleus pulposus (NP) surrounded by an annulus fibrosus (AF) present in between the cartilaginous endplates. B) Small extracellular vesicle (EV) biogenesis and composition. This illustration was created on the Wondershare Edraw Max Platform. (https://edrawmax.wondershare.com/).

https://doi.org/10.1371/journal.pone.0324179.g001

Regenerative medicine aims to repair ailing tissues and organs. Related mesenchymal stem cell (MSC) therapy could restore disc height and NP-MSCs have been identified in both degenerative and normal IVD tissues, showing a remarkable resilience to acidic conditions in vitro compared to other MSCs, alongside increased expression levels of key ECM components such as PGs and collagen II [55,58]. Transplanting NP-MSCs into the IVD for differentiation into NP cells is one regenerative approach for IVDD [59]. However, limitations with cell delivery and the harsh, hypoxic microenvironment in the mature NP challenges their viability in vivo, making successful long term therapy uncertain [10,38,6064]. Another strategy pursued in tissue regeneration is the activation of endogenous progenitor cells. It has been acknowledged that the MSC secretome plays an important part in immune modulation and regeneration [65,66]. The homeostasis of a microenvironment is naturally maintained via effective cell-cell communication [67]. The healthy NP is avascular and aneural [17,38,68,69] and possibly depended on small extracellular vesicle (EV) exchange for communication between isolated NP cells in the ECM. Small EVs with unique proteins, lipids, and nucleic acids specific to their parent cells are now recognized as intercellular communication methods [70]. Small EVs may interact with target cells, conveying cargo of bioactive molecules from parent to recipient cells thereby influencing their behavior and phenotypic traits by impacting cellular processes such as cell proliferation, differentiation, immune responses, and gene expression [7173]. Small EVs play significant roles in disease progression, including cancer and neurodegenerative disorders [74]. The development of large-scale “-omics” technologies has improved our understanding of the secretome, including EVs with specific cargo of proteins and nucleic acids [67,75]. Although the classification of EVs constantly changes [76] they usually fall into one of three categories based on size (Fig 1B): Apoptotic bodies (up to 5000nm), ectosomes (up to 1000nm), and small EVs (50–150nm), previously referred to as exosomes [72,77]. Recent guidelines recommend a nomenclature limiting the term “exosome” to only those small EVs demonstrated as generated via multivesicular bodies (MVB) [76]. Most cell types including resident stem- and progenitor cells produce small EVs, and their release into body fluids and culture media has sparked interest in the identification of cell or disease-specific biomarkers, similar to research in oncology [7883]. IVD small EV biomarkers could refine IVD cell phenotyping. Size, composition, functional influence on recipient cells, and the biological origin of small EVs all contribute to their heterogeneity [67,72]. The acellular nature of small EVs offers novel opportunities for IVDD therapy beyond constrains of stem cell therapies such as tumorigenesis, cell rejection or cell survival [75,84,85]. As part of the cell secretome, small EVs maintain the therapeutic benefits of their parent cell and protect their cargo via a phospholipid membrane [75,86]. Previous small EV research focused on the function and composition of NC cell derived EV microRNAs (miRNAs). These small non-coding RNAs are studied extensively for their therapeutic potential in other domains [87]. NC cell-derived EVs enhanced DNA and GAG content in human NP cell micro-aggregates compared to untreated controls, although the underlying mechanism and associated EV content were not determined [88]. Limited research has been conducted on IVD-derived EVs in the context of IVD homeostasis, largely focusing on benefits of MSC derived small EVs [85,86,8996]. In a recent study, EVs derived from NP cells promoted the proliferation of degenerated NP cells and reduced senescence in vitro, while attenuating IVDD in vivo [97], in another very recent study the cargo of small EVs generated by parent cells derived from degenerated human IVDs was investigated [98]. Identifying the best suited parent cell could be essential. Based on IVD location and anatomy, harvesting autologous cells of a healthy NP or AF could inflict organ damage (Fig 1). Adipose tissue is most readily accessible and has been a source for autologous MSC treatments for other conditions [99101]. However, dysfunctional fat metabolism and chronic activation of ERK/MAPK signaling has been linked to tissue aging in a number of animal models including humans [102104]. Investigating small EV cargo from NP and other parent cells could provide new insight into cell-cell communication and signaling cascades that maintain IVD homeostasis and point to novel strategies to prevent, delay or alleviate IVDD [6,75,89]. To address the potential of parent cell sources for small EV production we investigated the proteome of small EVs generated by autologous IVD and adipose tissue derived cells from healthy adult and fetal bovine donors and compared our novel data sets to existing MSC small EV data. Through gene ontology (GO) annotation and functional enrichment analyses we identified similarities and differences in the protein profiles of these small EVs. We further conducted quantitative small EV proteomics to compare NP small EVs with their parent cells. We found consistency with existing small EV data alongside proteins and molecular pathways relevant for NP cell homeostasis to serve as targets for the development of future IVDD interventions.

Materials and methods

Ethics statement

No human materials or subjects were used, no IRB required. No live animals were used. The work has been reported in line with the ARRIVE guidelines 2.0 and is covered under IACUC protocol/approval number 19−04, approved 10/24/2021. Project title: Analysis of Gene Expression. Institution: Clarkson University.

Isolation and culture of primary bovine adipose and IVD cell lines

Tails from skeletally mature, healthy adult cows were collected fresh as waste product from local abattoirs, stored on ice and immediately transported to the laboratory for dissection (Fig 2A and 2B). Skin, fat and skeletal muscle were removed, prior to isolating coccygeal IVDs flanking the caudal vertebras (cav) from the mid-tail section for tissue culture, typically cav7 to cav11. More proximal IVDs (>cav11) were fixed in 4% paraformaldehyde (PFA) for reference with histological stains like Mallory’s tetrachrome stain or RNA in situ hybridization (RISH) carried out as previously described (S1 Fig) [57,105]. Primary bovine cell-lines were isolated from finely minced tissue pieces of adult and fetal central NPs (referred to as NP), outer AFs (referred to as AF) and adipose tissues (referred to as FAT). The inner AF or transition zone of the IVD was discarded. Primary bovine cell-lines separated by tissue type and donor animal were maintained in Dulbecco’s Modified Eagles Medium (DMEM, GIBCO) with 10% (v/v) heat inactivated fetal bovine serum (HI-FBS performance, #16140071 (USA) GIBCO) and trypsinized with 0.05% Trypsin/EDTA (GIBCO) once 80–90% confluent as previously described [31,88] (Fig 2C2E). Cell lines isolated in that manner continued to express established cell markers (S1 Fig) [105]. Cells were aliquoted and stored in liquid nitrogen at passage (p) two or three. Culture media components and conditions were kept consistent for all cell lines and would therefore be comparable.

thumbnail
Fig 2. Isolation of parent cell lines and small EVs from bovine tissue.

A) Areas of a bovine coccygeal IVD for NP and AF tissue harvest are indicated by dotted lines. B) The green arrow points to subcutaneous adipose tissue after the skin was removed. C) AF cells in culture. D) NP cells in culture. E) Adipose tissue derived cells in culture. AF: Annulus fibrosus; FAT: Adipose tissue; NP: Nucleus pulposus. F) Simplified illustration of the workflow for small EV harvesting and downstream analysis. AF: Annulus fibrosus; DLS: Dynamic light scattering; DUC: Differential ultracentrifugation; EVs: Extracellular vesicles; FAT: Adipose tissue; FBS: fetal bovine serum; MS: Mass spectrometry; NP: Nucleus pulposus; SEM: Scanning electron microscopy; VB: Vertebral body; WB: Western blot.

https://doi.org/10.1371/journal.pone.0324179.g002

Small EV isolation from primary IVD cells

For small EV harvest cells were expanded to ~70% confluency in 20 x 150 mm culture dishes, washed three times with 1 × phosphate-buffered saline (PBS), then cultured in a total of 300 ml DMEM with 10% (v/v) small EV-depleted FBS (ED-FBS #A27208-03 (USA,GIBCO). After 48 h at 37˚C under normal oxygen and 5% CO2 supernatants were harvested for small EV isolation. A total cell count was estimated from the average of three 150 mm plates. Cells from two plates were lysed in cold 1 × RIPA lysis buffer (50 mM Tris HCl, 150 mM NaCl, 1.0% (v/v) NP40, 0.5% (w/v) sodium deoxycholate, 1.0 mM EDTA, 0.1% (w/v) SDS and 0.01% (w/v) sodium azide, pH 7.4) and stored at −80˚C for further protein analysis. One plate from each cell line was subjected to senescence associated (SA)-β-galactosidase staining for quality control [106]. Cell lines were only included in the study if deemed not senescent. Three biological replicates, NP cell lines TT32, TT33, and TT39 from healthy, adult donors were used for the quantitative proteome analysis of NP small EVs, while NP, AF and FAT cell lines TT39 and fetal (170 days of gestation) NP cells were used for explorative analysis of small EV proteome cargo.

Small EVs for proteome analysis were generally isolated as illustrated (Fig 2F) using differential ultracentrifugation (DUC) [107,108]. Cell debris was eliminated at 300 × g in an Eppendorf 5810 centrifuge followed by filtration of the supernatant (0.22 µm cut-off). Larger EVs were removed from the supernatant through DUC at 2000 (2k) × g for 30 min at 4ºC in a J2-21 Sorvall ultracentrifuge (rotor JA-20), followed by 10k × g for 1 h at 4ºC and 130 k × g for 2 h at 4˚C in a Beckman Optima XPN-100 ultracentrifuge (rotor Ti45). Each pellet was resuspended in 1 × PBS and stored at −80˚C. Final pellets were washed with 1 × PBS and repelleted at 130 k × g for 2 h at 4˚C before the final resuspension of the small EV fraction in 1 × PBS and storage at −80ºC. Triplicate measurements of protein concentration were conducted with a NanoDrop ND-1000 spectrophotometer (ThermoFisher Scientific) and Bradford assay. All solutions and consumables were nuclease and protease-free. Water or 1 × PBS was filtered with a 0.22 µm cut-off to eliminate dust particles.

Senescence associated (SA)-β galactosidase staining

Quality of parent cells was assessed via SA-β-Galactosidase staining at the time of small EV harvest and only deemed suitable if less than 10 senescent cells per confluent 150 mm plate were identified by blue staining. Staining was carried out at pH 6 with a staining solution of 1 mg/mL 5-bromo-4-chloro-3-indolyl-beta-D-galacto-pyranoside (X-gal), 5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, 150 mM NaCl and 2 mM MgCl2 in 40 mM citric acid/sodium phosphate buffer at pH 6 [106,109].

Western blot (WB) analysis

Protein samples were separated on a 12% SDS acrylamide gel (Biorad) and transferred to a nitrocellulose membrane (Biorad) at 90 volts for 120 min in 1 × transfer buffer. Membrane blocking was done for 2 h at room temperature, followed by overnight incubation with a primary antibody at 4°C. The membrane was washed 3 × with 1 × Tris buffered saline with Tween 20 (TBST), reblocked for 2 h, and incubated for 2 h at 4°C with the goat anti-rabbit IgG, cross-adsorbed, and horseradish peroxidase (HRP) conjugated secondary antibody (1:5000, ThermoFisher Scientific). Primary antibodies used in this bovine study included CD63 (rabbit, polyclonal (1:1000, Proteintech), TSG101 (rabbit, polyclonal (1:1000, ThermoFisher Scientific)), and Calnexin (rabbit, polyclonal (1:1000, ThermoFisher Scientific). SuperBlockTM PBS Blocking Buffer was used for all blocking and antibody dilutions (ThermoFisher Scientific). The chromogenic 1-StepTM TMB-Blotting Substrate (ThermoFisher Scientific) was used to visualize protein bands.

Dynamic light scattering (DLS)

Particle analysis was performed by estimating the hydrodynamic diameter of particles present in the different fractions with a Nanobrook 90Plus (Brookhaven Instruments). Samples for DLS were prepared as a suspension. 25 µl of each sample were resuspended well and diluted 1:80 in 1 × PBS before triplicate measurements. After stabilization of laser and temperature of the device, the following parameters were set for reproducibility and standardization: Laser Wavelength: 659 nm, dust cut-off: 40, angle: 90°, temperature: 25°C. Each DLS measurement consisted of 10 acquisitions for 5 sec each. BIC Particle Sizing software from Brookhaven Instruments was used for data acquisition and analysis. Particle size distribution data were presented graphically and numerically, showing the relative particle amount at each size and the cumulative undersize distribution.

Scanning electron microscopy (SEM)

Small EVs were fixed in 2% PFA, applied to a Formvar coated 400 mesh copper grid (EMS), post fixed with 1% glutaraldehyde, stained for 2 min with UranyLess (EMS) at room temperature, rinsed with deionized water, and imaged on a JEOL JSM 7900F-LV FESEM at 30kV in with a specialty STEM-in-SEM holder. Two technical replicates from one or two biological replicates were generated depending on the cell line.

Database generation

An extensive library of bovine small EV proteins was generated by integrating data from UniProt [110] and ExoCarta [111]. The ExoCarta proteins were renamed with the UniProt ID mapping tool for subsequent analysis. To identify putative bovine small EV proteins, human small EV protein sequences were searched against bovine protein sequences obtained from UniProt using the Basic Local Alignment Search Tool (BLAST) [112]. The BLAST results were merged with the bovine small EV protein sequences, and all sequences were clustered using CD-HIT v4.6.8 with a sequence identity threshold of 0.95 and a minimum length of 100 [113]. For the explorative bovine small EV proteome profile study, we also used a comprehensive umbilical cord MSC (UCMSC) small EV proteome database [114].

Small EV protein analysis by liquid chromatography-tandem mass spectrometry (LC-MS/MS)

To deplete high-abundance proteins, extracted small EV proteins were processed with the Pierce albumin and IgG removal kit (P/N 89875 ThermoFisher Scientific) according to the manufacturer’s protocol, which allows the analysis of less abundant proteins. In brief, after the gel slurry was washed, the sample was loaded into the gel slurry and incubated with the orbital rotator for 10 min at room temperature. Then, the flow-through was collected at 10,000 × g for 1 min using the spin column. The elution was repeated with the binding and elution process using 75 µl of the binding/wash buffer to obtain the non-redundant proteins.

Depleted small EV proteins were dissolved in protein buffer (8 M Urea, 0.1% SDS, 25 mM Triethylammonium Bicarbonate, pH 8.0) and quantified following a previous method [115]. Protein assays were performed to quantify purified proteins by the EZQ™ Protein Quantification Kit (Thermo Fisher Scientific, San Jose, CA, USA) with the SoftMax Pro Software v5.3 under the SpectraMax M5 (Molecular Devices, LLC). For each sample, a total of 10 μg of protein was reduced with 40 mM DTT, alkylated with 100 mM 2-chloroiodoacetamide, and trypsin-digested (at an enzyme-to-protein ratio (w/w) of 1:100). Tryptic digested peptides were desalted with C18-solid phase extraction (The Nest Group, Inc., Southborough, MA) for the capture of polar and non-polar peptides. Briefly, after equilibrating the cartilage with 1 ml of acetonitrile and 2 ml of water in 0.1% TFA sequentially. The peptide samples were passed over the columns three times before they were washed with 0.1% TFA. The peptides retained on the Sep-Pak C-18 column were eluted in 1 ml of 80% acetonitrile in 0.1% TFA, and the eluant was in the lyophilization.

The hybrid trapped ion mobility-quadrupole time-of-flight mass spectrometer (timsTOF fleX, Bruker Daltonics, Bremen, Germany) with a modified nano-electrospray ion source was interfaced with an ultra-performance EvoSep One LC system (Evosep Biosystem, Odense, Denmark). Briefly, Evotip was wetted with 100 µl of 100% iso-propanol, rinsed with 20 µl of Solvent B (99.9% acetonitrile and 0.1% formic acid (v/v)), equilibrated with 20 ul of 0.1% formic acid (v/v), loaded with 200 ng of digested peptides, and subsequently washed with 20 ul of 0.1% formic acid (v/v) using centrifugal force at 700 x g for 1 min. 100 μl of 0.1% formic acid were added to Evotip to prevent drying. Samples were injected into the Bruker timsTOF fleX MS coupled with the Evosep One instrument (Evosep Biosystems). The standard preset method of 15 SPD was used with the EV1106 Endurance column (Evosep One Biosystem) with 200 ng injection. The spectrum library was produced in the data-dependent mode with Parallel Accumulation Serial Fragmentation (PASEF) to improve ion utilization efficiency and data acquisition speed. The dual TIMS operated the system at 100% duty cycle and recorded the MS/MS mode scanning from 100 to 1700 m/z. The ion mobility was scanned from 0.6 to 1.6 Vs/cm-2, and TIMS ion charge control was set to 5e6. The TIMS dimension was calibrated linearly using three selected ions from the Hexakis (1H, 1H, 2H-difluoroethoxy) phosphazene, Hexakis (1H, 1H, 3H-tetrafluoropropoxy) phosphazene Agilent ESI LC/MS tuning mix [m/z, 1/K0: (622.0289, 0.9915 Vs cm-2), (922.0097, 1.1996 Vs cm-2), (1221,9906, 1.3934 Vs cm-2)] in positive mode.

Data searching, identification, and quantification

The MS/MS data were extracted peak lists under Data Analysis (Bruker Daltonics, Bremen, Germany; version 6.1) and analyzed with Mascot (Matrix Science, London, UK; version 2.7). Mascot was set up to search against the customized protein database described above (customized 5,922 contigs) with a decoy database for false discovery rate (FDR) using digestion enzyme trypsin/Lys-C, parental ion tolerance of 15 ppm and fragment ion mass tolerance of 0.5 Da, respectively. Carbamidomethyl of cysteine (+57.021 Da) was set as the static modification, and oxidation of methionine (+15.995 Da), deamidation of glutamine and asparagine (+0.984 Da), pyro-glutamine formation from N-terminal glutamine (−17.026 Da), as well as phosphorylation of serine, threonine, and tyrosine (+79.966 Da) were specified as the variable modifications. Scaffold Q + S (Proteome Software Inc., Portand, OR, USA; version 5.4.2) was used to validate MS/MS based peptide and protein identifications. Peptide identifications were accepted if they could be established at greater than 95.0% probability by the Peptide Prophet algorithm. Protein quantification was accepted if they could be established at greater than 95.0% probability at significance with at least three peptides with 99.9%. Differences in protein abundance between NP cells and NP small EVs were evaluated using Student’s t-test. To be identified as being significantly differentially abundant, proteins should be quantified with at least four unique peptides in both experimental replicates with a p < 0.05 and a fold change >1.5 or <0.5.

Gene ontology analysis, network and clustering of small EV proteins

The gene ontology (GO) and functional enrichment analysis of differentially abundant NP small EV proteins, IVD small EV proteins (NP, AF, and fetal NP), and FAT small EV proteins was performed using the Bioinformatics Resources 6.8 Database for Annotation, Visualization, and Integrated Discovery (DAVID) and the number of genes associated with each term, and enrichment bubble plots were generated using SRplot [116]. Alternatively, ToppFun of the ToppGene Suite was utilized (FDR correction and p-value cut-off 0.05) [117]. Using the search tool for the retrieval of interacting genes/proteins (STRING) database [118], a protein network was built for more abundant and all NP small EV proteins. For medium confidence network construction, default settings were employed. To find clusters in the created protein network, the Markov clustering algorithm (MCL) was utilized and carried out with an inflation parameter of 3. Following clustering, biological processes (BP), molecular functions (MF), and cellular components (CC) clusters were examined in the context of NP small EV protein function. Venny 2.1 (https://bioinfogp.cnb.csic.es/tools/venny/index.html) was used for comparison.

Results

Small EV isolation

Small EVs were confirmed in the final DUC fraction for all primary bovine parent cell lines through the presence of established small EV markers CD63 and TSG101 and the absence of the cellular marker Calnexin via spectral counts and, if sufficient material was available, by Western blot as shown exemplarily for NP parent cells (Figs 3A3C and S2). The expected particle size range for small EVs (50–150 nm) was confirmed by DLS (Fig 3D) and ImageJ analysis of SEM micrographs (Fig 3E and 3F). The protein concentration in each small EV fraction was calculated per cultured parent cell (S1 Table).

thumbnail
Fig 3. Characterization of small EVs.

A) Spectrum for CD63, a cell surface protein of the tetraspanin family and small EV marker. B) Spectrum for tumor susceptibility gene 101 (TSG101), a small EV marker. C) Spectrum for calnexin (CNX), a cell marker. D) DLS data showing the relative amount of particles at each size and the cumulative undersize distribution of small EVs from each parent cell line. E) Scanning electron microscopy (SEM) imaging of small EVs from each parent cell line. The scale bar represents 100 nm. F) Size distribution of DUC purified small EVs determined using ImageJ (n = 150 (NP), n = 157 (AF), n = 130 (FAT), n = 216 (fetal NP)). AF: Annulus fibrosus; DLS: Dynamic light scattering; DUC: Differential ultracentrifugation; EV: Extracellular vesicle; FAT: Adipose tissue; NP: Nucleus pulposus; VB: Vertebral body.

https://doi.org/10.1371/journal.pone.0324179.g003

Bovine small EV protein database

A bovine small EV protein database was constructed by integrating small EV proteins from ExoCarta [111] and bovine proteins from UniProt [110]. A total of 47,128 bovine protein sequences was downloaded from UniProt, while ExoCarta provided 1,416 bovine and 6,514 human small EV proteins as of October 2, 2023. The BLAST results of human small EV proteins against 47,128 bovine protein sequences resulted in 4,972 bovine proteins, which were merged with bovine small EV proteins obtained from ExoCarta. After sequence clustering with 1,416 bovine small EV proteins and 4,972 bovine proteins homologous to human small EV proteins, the final bovine small EV protein database BOVXCU24 (accessible via PXD056784 and MSV000096081) had 5,922 unique entries.

Proteome profiling of bovine small EVs

For profiling purposes small EV proteins were first identified in a non-quantitative manner. Small EVs harvested from fetal or adult primary bovine parent cells were compared to existing small EV and MSC small EV data.

Bovine small EV proteins in the context of existing data.

Of the here identified bovine small EV proteins, 479 were shared with ExoCarta [111] or Vesiclepedia [119], both evolving databases for (small)EV research. Our bovine small EV data was essentially consistent with findings by Kugeratski et al. identifying Syntenin 1 (syndecan binding protein (SDCBP)) alongside GTPases and membrane proteins such as an integrin subunits and the “classic” tetraspanin small EV markers CD9, CD63 and CD81 [120]. Other established small EV markers such as the programmed cell death 6 interacting protein (PDCD6IP or ALIX) [121] and the tumor susceptibility marker TSG101 known for its role in vacuolar sorting and small EV biogenesis [122] were also detected. Transcripts for these proteins were previously described for the parent cell lines(Tables 1, S2 and S3) [105]. The bovine small EV proteins shared with these small EV databases were associated with a range of biological pathways through functional enrichment analysis in DAVID (Fig 4A) and ToppFun (Fig 4B). Among those, based on fold enrichment over background, the top five highest ranking pathways by fold change (FC) in the KEGG database were proteasome (bta03050), pentose phosphate pathway (PPP) (bta00030), glycolysis/gluconeogenesis (bta00010), complement and coagulation cascades (bta04610), and ECM receptor interaction (bta04512) (Fig 4A). Analysis in ToppFun identified the (innate) immune system (Reactome MM14661), neutrophil degeneration (Reactome M27620), hemostasis (Reactome M8395), nervous system development (M29853), integrin1 (Pathway Interaction Database (PID) M18), and ephrin signaling (Reactome, M27201) amongst the top 200 pathways (Fig 4B, S4 Table).

thumbnail
Table 1. Functional enrichment analysis (DAVID) of shared proteins among bovine small EV proteins and the ExoCarta and Vesiclepedia databases.

https://doi.org/10.1371/journal.pone.0324179.t001

thumbnail
Fig 4. Bovine small EVs and existing data.

(A) KEGG pathway analysis in DAVID and (B) ToppFun pathway analysis of 479 shared proteins. DAVID: Database for annotation, visualization, and integrated discovery; KEGG: Kyoto encyclopedia of genes and genomes.

https://doi.org/10.1371/journal.pone.0324179.g004

Small EV proteins from autologous parent cells of different tissues.

First, proteome profiling of autologous small EVs isolated from bovine IVD (NP and AF) and adipose (FAT) cells was conducted in an explorative, non-quantitative manner to identify NP parent small EV unique protein signatures. Of the small EV proteins identified for AF, NP and FAT parent cells, a core of 102 (30%) were shared. Functional enrichment analysis in DAVID associated those proteins with a range of important pathways (Fig 5, Table 2). An additional 156 small EV proteins were only identified for NP parent cells. Based on their pathway association in DAVID a metabolic theme stood out, especially the PPP (bta00030) showed a high FC and significance. Associations relevant to NP cell function such as L-ascorbic acid binding (GO:0031418), angiostatin binding (0043532), and general protein stabilization (GO:0050821) were also noted amongst many others (Tables 2 and S5). Functional enrichment analysis in DAVID of the additional 24 small EV proteins shared only between NP and AF parent cells were involved in regulation of the cytoskeleton (bta04810), focal adhesion (bta04510) and endocytosis (bta04144), while additional 43 small EV proteins common only to NP and adipose (FAT) parent cells associated with functions and pathways of the 20S proteasome (KEGG, bta03050). Other small EV proteins in this group were involved with the citrate cycle (bta00020) or calcium ion binding (Figs 5 and S3, Table 2). ToppFun identified 39 pathways common to small EV proteins of all three autologous parent cells, including but not limited to the (innate) immune system, nervous system development, and programmed cell death. Additional 24 were shared only between small EV proteins of NP and AF parent cells and 75 between NP and FAT parent cells (Fig 5D, S6 Table). Among the 23 pathways only associated with small EV proteins from NP parent cells were glycolysis and gluconeogenesis (KEGG, WP) and the PPP (KEGG) represented by glyeraldehyde-3-phosphate dehydrogenase (GAPDH), aldo-keto reductase family member A1 (AKR1A1), phosphofructokinase (PFKL), phosphoglucomutase 1 (PGM1), alcoholdehydrogenase 5 (ADH5), pyruvate kinase (PKLR, PKM), aldehydedehydrogenase 3 and 9 family members (ALDH3B1, ALDH9A1), fructose-bi-phosphate aldolases (ALDOA, ALDOC) glucose-6-phosphate isomerase (GPI), lactate dehydrogenases (LDHA, LDHB), triosephosphate isomerase 1 (TPI1), transketolase (TKT), and glucose-6-phosphate dehydrogenase (G6PD). Also identified was signaling by the Roundabout (ROBO) family (Reactome), transmembrane receptors involved in axon guidance and cell migration through the association with several proteasome 20S subunits, two ribosomal proteins, profilins (PFN1, PFN2), vasodilator stimulated phosphoprotein (VASP), cyclase associated actin cytoskeleton regulatory protein1 (CAP1), RAC family small GTPase 1 (RAC1), protein kinase cAMP-dependent type II regulatory subunit alpha (PRKAR2A), and cell division cycle 42 (CDC42) (S6 Table). Transcripts for these proteins were previously described for the parent cell lines (S3 Table) [105].

thumbnail
Table 2. KEGG pathways identified through functional enrichment analysis (DAVID) comparing small EV proteins of autologous bovine NP, AF, and FAT parent cells.

https://doi.org/10.1371/journal.pone.0324179.t002

thumbnail
Fig 5. Profiling of small EV proteins from autologous bovine parent cells.

A) Venn diagram comparing small EV proteins from autologous NP, AF, and FAT parent cells. B) KEGG pathway analysis in DAVID of 102 shared proteins and (C) KEGG pathway analysis in DAVID of 156 proteins unique to NP small EVs. D) ToppFun pathway analysis of top 200 shared pathways. AF: Annulus fibrosus; DAVID: Database for annotation, visualization, and integrated discovery; FAT: Adipose tissue; KEGG: Kyoto encyclopedia of genes and genomes; NP: Nucleus pulposus.

https://doi.org/10.1371/journal.pone.0324179.g005

Small EV proteins from adult or fetal NP and MSC parent cells.

A comparison of the small EV protein profile of adult and fetal NP parent cells with that of MSC small EVs was conducted to investigate if NP small EV proteins can positively impact on cell homeostasis or progenitor cell mobilization. In this study, data from human umbilical cord mesenchymal stem cells (UCMSCs) was chosen for comparison as it was the most comprehensive MSC small EV protein dataset at the time of the analysis [114]. Of the small EV proteins identified, 206 were shared between fetal NP, adult NP, and UCMSC parent cells; additional 37 only between fetal and adult NP parent cells; 67 only between adult NP and UCMSC parent cells; and 37 only between fetal NP and UCMSC parent cells. Another 13 and 15 were only identified in small EVs of fetal or adult NP cells, respectively (Fig 6A). Functional enrichment analysis by DAVID of the 206 shared small EV proteins identified proteasome (bta03050), PPP (bta00030) and glycolysis/gluconeogenesis (bta00010) as pathways with high significance and highest FC (Figs 6B and S4, Table 3). DAVID analysis associated the 37 small EV proteins identified for fetal NP and UCMSC parent cells essentially with endocytosis and vesicle formation, while small EV proteins shared between UCMSC and adult NP parent cells related to metabolism, though the FC was low (Fig 6C6E, Tables 3 and S7). ToppFun pathway analysis for each of the three parent cell lines identified a total of 74 pathways common to all three sources, including the platelet-derived growth factor receptor β (PDGFRB) pathway (PID), and β-catenin independent WNT signaling (Reactome) (Fig 6F, S8 Table). Among pathways linked to small EV proteins from UCMSC and adult NP parent cells were signaling by ROBO receptors (Reactome) and for UCMSC and fetal NP parent cells signal transduction by growth factor receptors and second messengers (Reactome). Many of the 59 pathways associated with small EV proteins shared between adult and fetal NP parent cells affected various signaling pathways including Notch signaling, but often through their proteasome association. Glycolysis/gluconeogenesis (KEGG) and aerobic glycolysis (WP) was identified, essentially via most proteins mentioned for glycolysis above (Tables 3, S7 and S8). Hematopoietic stem cells are amongst the best studied progenitor cells and can be mobilized through the G-protein-coupled chemokine receptor CXCR4 and its ligand CXCL12 [123]. These proteins were not detected in small EVs here, though transcripts for both were previously identified in NP cell lines with 5.9 and 1.8 transcripts per million (TPM), respectively [105]; and an association with the CXCR4 pathway (PID, M124) was suggested for small EV proteins shared between adult and fetal NP parent cells based on the identification of 14 proteins containing several integrin and G-protein subunits, receptor for activated C kinase (RACK1), RAC1, vacuolar protein sorting 4 homolog B (VPS4B), RAS homolog family member A (RHOA) and CDC42. Transcripts for all were previously identified in NP cell lines [105].

thumbnail
Table 3. KEGG pathways identified through functional enrichment analysis (DAVID) comparing small EV proteins of adult and fetal NP cells with UCMSC cells.

https://doi.org/10.1371/journal.pone.0324179.t003

thumbnail
Fig 6. Nucleus pulposus and MSC small EV profiling.

A) Comparison of small EV proteins from fetal and adult NP parent cells to those of UCMSCs (128). B) KEGG pathway analysis in DAVID of 206 shared proteins (C) KEGG pathway analysis in DAVID of small EV proteins shared by fetal NP and UCMSC parent cells. D) KEGG pathways analysis in DAVID of small EV proteins shared between adult NP and UCMSC parent cells. E) Functional enrichment analysis in DAVID of 13 proteins only identified for fetal NP small EVs. F) ToppFun pathway analysis of top 200 shared pathways. DAVID: Database for annotation, visualization, and integrated discovery; KEGG: Kyoto encyclopedia of genes and genomes; NP: Nucleus pulposus; UCMSCs: Umbilical cord mesenchymal stem cells.

https://doi.org/10.1371/journal.pone.0324179.g006

Comparative analysis of the NP small EV and parent proteome

Bioactive molecules in the membrane or lumen of small EVs might end up there by chance, reflecting their abundance in the parent cell, or they could be deposited/ removed during small EV biogenesis. To identify differentially abundant small EV proteins, quantitative proteomics of NP small EVs and their respective parent cells was conducted. We identified a total of 151 differentially abundant proteins, which were subjected to functional enrichment analysis using DAVID and ToppFun (Figs 7 and S5, Tables 4, S9 and S10), then protein clusters were visualized in STRING (Fig 8).

thumbnail
Table 4. KEGG pathways identified through functional enrichment analysis (DAVID) after quantitative comparison of NP small EV and parent cell proteins.

https://doi.org/10.1371/journal.pone.0324179.t004

thumbnail
Fig 7. Quantitative functional enrichment analysis of NP small EV proteins.

A) KEGG pathway analysis and (B) ToppFun pathway analysis of 141 proteins more abundant in NP small EVs as compared to their parent cells. C) Functional enrichment analysis and (D) ToppFun pathway analysis of ten proteins reduced in NP small EVs as compared to their parent cells. DAVID: Database for annotation, visualization, and integrated discovery; KEGG: Kyoto encyclopedia of genes and genomes; NP: Nucleus pulposus.

https://doi.org/10.1371/journal.pone.0324179.g007

thumbnail
Fig 8. Functional clusters of more abundant NP small EV proteins.

A) STRING network of 141 more abundant NP small EV proteins; B) Cluster 1: Complement component C1q complex (red), complement and coagulation cascades (blue), complement activation classical pathway (green); C) Cluster 2: Proteasome (red); D) Cluster 3: Axon (blue), axon guidance receptor activity (red), Ephrin signaling (green); E) Cluster 4: Ras signaling (red), axon guidance (green) and MAPK signaling pathway (blue); F) Cluster 5: Hemostasis (green), regulation of MAPK cascade (blue), complement and coagulation cascades (red); G) Cluster 6: ECM (pink), integrin binding (light green), collagen binding (sky blue), ECM receptor interaction (red), PI3K/AKT signaling pathway (blue), ECM organization (yellow), signaling by RTKs (dark green). STRING: Search tool for the retrieval of interacting genes/proteins; NP: Nucleus pulposus.

https://doi.org/10.1371/journal.pone.0324179.g008

Differentially abundant NP small EV proteins.

Of the 151 proteins identified as differentially abundant, 141 proteins were more abundant in NP small EVs and ten less abundant relative to their parent cells (Tables 4, S9 and S10). Amongst the more abundant proteins were Syntenin 1 (SDCBP), integrin subunit β1 (ITGB1) and many GTPases, consistent with the small EV core proteome [120]. Pathways were associated with important cell signaling cascades as well as cell and niche homeostasis as described in more detail below (Figs 7 and S5). While no pathways were identified for the ten less abundant proteins using DAVID, these proteins were involved with posttranslational modifications such as oligosaccharyltransferase (GO:0008250) and N-linked glycosylation (GO:0006487), and as coenzyme in the biosynthesis of amino acids, neurotransmitters and sphingolipids via pyridoxal phosphate (PLP) binding (GO:0030170). They further associated with mitochondria (GO:0005739) and mitochondria matrix (GO:0005759) (Fig 7C, Tables 4 and S9). Functional enrichment using ToppFun identified amino acid metabolism (WP, M39570), transaminase activity (GO:0008483) and glutamate and glutamine metabolism (Reactome, M27851) as associated with underrepresented NP small EV proteins through an association with glutamic-oxaloacetic transaminase 2 (GOT2), tryptophanyl-tRNA sythetase 1 (WARS1) and ornithine aminotransferase (OAT). The mitochondrial lactate dehydrogenase A like 6B (LDHAL6B) was also underrepresented (Fig 7D, S9 and S10 Tables). Transcripts for all were previously detected in NP cells, LDHAL6B at very low levels though (S3 Table) [105].

More abundant NP small EV proteins with immunomodulatory and housekeeping functions.

STRING analysis of the 141 more abundant NP small EV proteins revealed at least six distinct clusters (Fig 8A). The healthy NP is considered immune privileged [124], yet important elements in the innate immune response were identified in cluster 1 as relevant for complement activation and opsonization, including proteins associated with the complement component C1Q complex (GO:0062167), complement and coagulation cascades (bta04610) and complement activation classical pathway (WP977). The cluster contained most members of the complement cascade (C1 to C9) alongside the opsonins Pentraxin 3 (PTX3) and mannose binding lectin 2 (MBL2); the complement activating component mannose-binding lectin-associated serine protease 1 (MASP1); and Apolipoprotein E (APOE), an inhibitor of the classic complement cascade via C1Q binding [125] (Fig 8B). Transcripts for all proteins except MBL2 including various members of the complement complex, except C1Q and C4, were previously identified for NP cells, though typically with very low TPM (S3 Table) [105]. Notably, no interleukins were identified despite their transcription in NP parent cells (S2 and S3 Tables) [105]. Proteasomes, intracellular non-lysosomal protein degradation complexes, as seen in cluster 2 have important functions in cell homeostasis, physiology and development [126]. This cluster was comprised of subunits of the standard 20S proteasome, namely α3, α4, β1,β2, β4, and β6 (Fig 8C, Table 4). Transcripts for all proteasome units were previously identified for NP cells [105].

More abundant NP small EV proteins participate in cell signaling.

Small EV proteins can be associated with the small EV membrane as ion channels, transporters, receptors, or internal cargo. Of the 141 more abundant NP small EV proteins 38% were membrane associated. Amongst those were seven receptor tyrosine kinases (RTK), all of the EPH receptor type, two Notch receptors (NOTCH 2 and 3), one chloride anion channel (Tweety homolog 3 (TTYH3)), the auxiliary subunit of a calcium-voltage gated channel (CACNA2D1), and the insulin-like growth factor 2 receptor (IGF2R). All proteins have been previously identified as small EV associated and transcripts for all were previously identified for NP cells (Tables 4 and S3) [105,111].

EPH receptor tyrosine kinase (RKT) – RAS/MAPK signaling axis: Cluster 3 was composed of nine NP small EV proteins (Fig 8D). Of those the Ephrin receptors EPHB1, EPHB2, EPHB3, EPHB4 and the RAC family small GTPase 1 (RAC1), a plasma membrane associated small GTPase involved in a range of cellular events [127129], associated with the term ephrin signaling (bta3928664). EPHB1, EPHB2 and EPHB3 additionally associated with the term axon guidance receptor activity (GO:0008046), and EPHB1, EPHB2 and Neuropilin 2 (NRP2), a transmembrane protein and high-affinity receptor for some semaphorins [130], with the term axon (GO:0030424). Several components of the RAS pathway signaling cascade were also enriched in NP small EVs, forming the small cluster 4. Part of this cluster were RAS proto-oncogenes and GTPases NRAS, RRAS and RRAS2, also PlexinB2 (PLXNB2), a cell surface receptor for semaphorins, associating with the RAS (bta04014) and MAPK (bta04010) signaling pathways as well as axon guidance (bta04360) (Fig 8E). Cluster 5 consisted of 20 NP small EV proteins associated with the regulation of MAPK cascade (GO:0043408), namely the fibrinogen α (FGA), β (FGB) and γ(FGG) chains and angiotensinogen (AGT) (Fig 8F). Transcripts for all proteins but EPHB1, FGA and AGT were previously identified for NP cells, though some with low TPM (S3 Table). Interestingly, transcripts for ephrin ligands (EFNA1–5 and ENFNB1–3) were previously detected in NP cells, however, the ligands were not enriched in NP small EVs (S2 and S3 Tables) [105].

ECM-integrin signaling axis: The largest cluster 6 contained 29 more abundant NP small EV proteins associated with ECM structural constituents (GO:0005201), ECM organization (GO:0030198) and ECM receptor interaction (bta04512), integrin- (GO:00005178) and collagen- (GO:00005518) binding. Amongst the proteins in cluster 6 were collagens (COL) 1, 2, 3, 5, 6, 11 and 12, various integrin subunits (ITG), laminins (LAMA5, LAMB1, LAMC1), and Keratin 18 (KRT18) an intermediate filament. Also, Matrix metalloproteinase 2 (MMP2), Transforming growth factor βinduced (TGFβI) and more (Fig 8G). Especially the laminins and integrins but also COL1 and COL2 were associated with PI3K/AKT signaling (bta04151) through RTK signaling (bta9006934) and ECM receptor interaction (Fig 8G). Transcripts for all but KRT18 were previously identified for our NP cells (S3 Table) [105].

NP small EV proteins with links to major cellular events

STRING was also used to identify NP small EV protein clusters (Fig 9A) based on all confirmed 484 NP small EV proteins identified here, not limited to those differentially abundant in NP small EVs over their parent cells described above (S2 Table). The cluster of 22 proteins in Fig 9B, identified proteins involved in small EV biogenesis and the endosomal sorting complex (ESCRT). The largest cluster in Fig 9C contained 87 NP small EV proteins and was dominated by carbon metabolism (bta01200) with associations to metabolic processes including but not limited to core processes in energy production, with GAPDH taking on a central role (Fig 9C). Also, part of this cluster were proteins involved in oxidative stress associated hypoxia inducible factors (HIF) signaling (bta04066), glutathione metabolism (bta00480), and proteins associated with pathways downstream of PI3K/AKT signaling (R-bta-111447, R-bta-9614399). A cluster of eight proteins involved in GPCR signal transduction in Fig 9D showed ties to axon guidance and Schwann cell migration. The cluster of 11 proteins in Fig 9E associated with EPHB-mediated forward signaling (R-bta-3928662) and connected to other important signaling pathways such as signaling by RHO GTPases (R-bta-194315) and VEGFA/VEGFR2 (R-bta-4420097). The small cluster of six proteins in Fig 9F related to the RAS proto-oncogenes which are crucial in many signal transduction pathways including the RAS (bta04014), PI3K/AKT (bta04151) and MAPK (bta04010,) signaling pathway and related MAP2K and MAPK activation (R-bta-5674135). The cluster of 11 proteins in Fig 9G9H was largely composed of different integrin subunits, fibronectin (FN1) and the integrin-linked kinase (ILK), all involved in a range of biological processes including cell adhesion (GO:0033627), mesodermal cell differentiation (GO:0048333), angiogenesis (GO:0001525), regulation of small GTPase mediated signal transduction (GO:0051056), negative regulation of apoptotic process (GO:0043066) and ties to ECM receptor interaction (bta04512), focal adhesion (bta04510), TGFβ signaling (WP1045), the PI3K/AKT signaling pathway and axon guidance (bta04360). The cluster of nine proteins seen in Fig 9I essentially associated with biological processes such as actin filament polymerization (GO:0030041), actin cytoskeleton organization (GO:0030036,) and positive regulation of lamellipodium (GO0010592), hence affiliated with cell migration. The cluster of 26 NP small EV proteins shown in Fig 9J associated with the PI3K/AKT signaling pathway affecting a range of biological processes including ECM assembly (GO:0085029), cartilage development (GO:0051216), angiogenesis (GO:0001525), blood vessel development (GO:0001568) and cell adhesion (GO:0007155).

thumbnail
Fig 9. Functional clusters of all identified NP small EV proteins.

A) STRING network of 484 NP small EV proteins; B) Cluster 1: Extracellular vesicle biogenesis (red), multivesicular body sorting pathway (blue), ESCRT I complex (pink), ESCRT (green), Flotillin complex (yellow); C) Cluster 2: Detection of oxidative stress (black), pentose phosphate pathway (red), glycolysis/gluconeogenesis (blue), biosynthesis of amino acids (green), carbon metabolism (pink), pyruvate metabolism (dark green), TCA cycle (yellow), glutathione metabolism (sky blue), HIF1 signaling pathway (purple), amino sugar and nucleotide sugar metabolism (ochre yellow), activation of BAD and translocation to mitochondria (brown), regulation of localization of FOXO transcription factors (grey); D) Cluster 3: Regulation of Schwann cell migration (blue), G-protein coupled receptor signaling pathway (green), axon guidance (red); E) Cluster 4: Rac protein signal transduction (red), RAS protein signal transduction (blue), small GTPase mediated signal transduction (green), RAP1 signaling pathway (yellow), EPHB-mediated forward signaling (pink), VEGFA/VEGFR2 pathway (dark green), signaling by Rho GTPases (sky blue); F); Cluster 5: MAP2K and MAPK activation (red), RAS signaling pathway (green), MAPK signaling pathway (pink), PI3K/AKT signaling pathway (yellow); G) Cluster 6 version 1: Cell adhesion mediated by integrin (red), mesodermal cell differentiation (blue), angiogenesis (green), regulation of small GTPase mediated signal transduction (yellow), negative regulation of apoptotic process (pink); H) Cluster 6 version 2: ECM receptor interaction (red), focal adhesion (green), PI3K/AKT signaling pathway (blue), axon guidance (yellow), TGFβ signaling pathway (pink); I) Cluster 7: Positive regulation of lamellipodium assembly (blue), actin cytoskeleton organization (red), EPHB mediated forward signaling (green); J) Cluster 8: ECM assembly (pink), cartilage development (green), angiogenesis (blue), blood vessel development (red), cell adhesion (yellow), PI3K/AKT signaling pathway (dark green). ECM: Extracellular matrix; ESCRT I: Endosomal sorting complex required for transport I; STRING: Search tool for the retrieval of interacting genes/proteins; NP: Nucleus pulposus.

https://doi.org/10.1371/journal.pone.0324179.g009

Considerations regarding a serum corona

Recent work demonstrated that plasma proteins spontaneously form a corona around the surface of EVs or virus particles [131]. Many cells require fetal bovine serum (FBS) during in vitro culture. Of corona proteins reported for the serum of healthy participants [131], 11 were identified in our NP small EV protein data set, namely Clusterin (CLU); fibrinogen chains α, β and γ (FGA, FGB, FGG); complements C3 and C4; α1-acid protein 1 (ORM1); Ceruloplasmin (CP) involved in iron oxidation without the production of oxygen radicals thus preventing tissue damage; Inter-alpha-trypsin inhibitor heavy chains ITIH2, ITIH4; and Apolipoprotein E (APOE); with CLU, APOE and CP showing high (TPM > 2000) and moderate transcript levels (TPM 137 and 45) in NP cells, respectively. Amongst the three autologous parent cell types CLU transcript levels were previously found highest in NP cells. No transcripts were identified in NP, AF or FAT parent cell for ITIH2, FGA and C4, while only very low levels were detected for ITIH4 and ORM1. Amongst proteins found in viral coronas [131], APOB, APOE, C3 and C4 overlapped with our data set of NP small EV proteins, with C3 and APOB being low level or not transcribed, respectively (S3 Table) [105]. Via ToppFun we identified associations with pathways like neutrophil degranulation, innate immune system, immune system, platelet activation signaling and aggregation, nervous system, VEGFA/VEGFR2 signaling, focal adhesion and regulation of the actin cytoskeleton for small EV proteins by our parent cells and listed in the ExoCarta database. Associations with all three pathways of the complement system were only found in the data set of more abundant NP small EV proteins via CLU, a secreted chaperone protein and inhibitor of the complement membrane attack complex (MAC) and therefore cell lysis (S6 Fig, S11 Table).

Mass spectrometry analysis of the FBS used here for cell culture suggested a list of 523 proteins (S12 Table). After removing these serum related proteins from our data sets, functional enrichment analysis was repeated for the 119 remaining more abundant NP small EV proteins (S7 Fig). This serum protein depleted dataset still identified complement and coagulation cascades (bta04610, KEGG M16894, WP M39649) and axon guidance (bta04360, KEGG M5539), but now also affiliated with longevity regulating pathway (bta04211), efferocytosis (bta04148), cellular senescence (bta04218) and more. The longevity connection was established through the RAS GTPases NRAS, KRAS, RHEB, and ADIPOQ, a plasma protein with anti-inflammatory and antioxidant effects [132] involved in AMP-activated protein kinase (AMPK) signaling (bta04152) for which we previously detected low level expression in NP cells cultured under comparable conditions (S3 Table) [105]. Efferocytosis enables tissue homeostasis following distinct phases of finding, binding, internalization and breakdown of apoptotic cells [133] and was identified through C1QA, C1QC; the solute carrier SLC16A1 involved in transport of monocarboxylates like pyruvate and lactate and driven by the proton motive force [134]; integrin subunit (ITGB5); the disintegrin and metalloproteinase domain-containing protein (ADAM10) and the small GTPase RAC1. Association with cellular senescence was also established through small GTPases. Transcripts were previously detected for all but C1Q, though some transcripts encoding Complement C1q Like proteins were expressed in NP cells (S3 Table) [105]. ToppFun analysis further identified, integrin pathway (PID M18), ECM organization (Reactome M610, MM14572) and hemostasis (M8925) amongst the top pathways (S12 Table). Interestingly, EPH-ephrin mediated repulsion of cells (Reactome, M27311), EPH forward pathway (PID M62) and EPH-ephrin signaling (Reactome, M27201) remained significant, essentially through the EPH receptor-RAS signaling axis and ECM components (S12 Table).

Similar associations were observed for all 300 NP small EV proteins after removing the serum proteins from the dataset. Additional pathways of interest like signaling by NOTCH4 (Reactome M954), regulation of RUNX3 expression (MM15536), somitogenesis (Reactome, M48031), and stabilization of P53 (Reactome M27670) were essentially based on an affiliation with the proteasome 20 subunits (S7 Fig, S12 Table).

Discussion

Extracellular vesicle research is an evolving field, even more when it comes to cells of the IVD. Current technologies do not allow for proteomic analysis of IVD small EV cargo in vivo, in situ. Scaled-up cell culture remains inevitable at this time to study the NP small EV proteome. It is generally acknowledged that culture conditions can affect a cells’ secretome, which could cause data inconsistency. Discovery of novel or unique biomarkers associated with small EVs and/or parent cell lineages might have been obscured by the in vitro approach. To limit artifacts, the parent cells used here were exposed to identical media components and culture conditions, and experiments were conducted with biological and technical replicates, mitigating experimental bias as much as possible. We have investigated small EV proteins from autologous NP, AF and FAT parent cell sources as well as fetal NP tissue derived cells. Our data was compared to existing small EV data in a proteome centered approach backed up by previously acquired transcriptome data.

Amongst spine related health concerns IVDD is one of the major causes of lower back pain, a degenerative disease currently lacking a cure [6]. Regenerative stem cell therapies have been considered for IVDD; however, the harsh NP microenvironment poses a challenge. Small EVs, now regarded a tool of cell communication as part of many cells’ secretome, showed favorable therapeutic properties in various applications including increased cell proliferation, ECM synthesis, migration of repair-involved cells to an injury site, and promoted the differentiation of MSCs into NP cells while also showing reduced apoptosis, inflammation, ECM degradation, and cell senescence in NP cells [86,93,135]. A recent study highlighted the therapeutic potential of implementing a TIE2-positive (+) cell-enhancing protocol, emphasizing the importance of optimizing culture conditions. The EV product isolated from TIE2+ NP cells demonstrated promising regenerative outcomes, yet its cargo was not specifically characterized [97]. The focus of our analysis was to specifically investigate the NP small EV proteome for content and anticipated roles of NP small EV proteins in comparison to those of autologous AF and adipose cells, fetal NP cells and MSC. Our interpretation relays on multiple functional enrichment and pathway tools (DAVID, ToppFun, KEGG, STRING) with KEGG being more focused on disease related databases, ToppFun most up to date in its annotations and STRING considering known and predicted protein/protein interactions.

Bovine coccygeal IVDs are an accepted model for young, healthy human IVDs enabling the study of cell homeostasis under non-diseased conditions [105]. While bovine small EVs might show species and/or tissue specific variations that could affect their makeup and functionality the extensive overlap with existing small EV data is supportive of this approach. The majority of small EV proteins identified here were contained in the ExoCarta and Vesiclepedia databases. Despite much of the existing small EV data being based on body fluids such as urine and serum, or cancer cell lines, we found significant overlap. While we have not discovered any novel NP biomarkers based on their small EV proteome, we believe that the NP small EV proteome cargo makes important contributions to NP cell and tissue homeostasis as outlined below (Fig 10).

thumbnail
Fig 10. Multifaceted roles of the small EV proteome in NP cell and tissue homeostasis.

NP small EV protein cargo and membrane constituents are involved in key metabolic pathways, including glycolysis, gluconeogenesis, Krebs cycle and PPP. They are crucial for energy production and to maintain the cellular redox balance. NP small EVs with the aid of the 20S proteasome, ensure protein quality control and reduced inflammation in a recipient cell. NP small EVs modulate signaling through EPH receptors, impacting cellular communication and tissue organization. Additionally, NP small EV interact with the complement system, influencing the classical, alternative, and lectin pathways involved in immune responses and inflammation. The PI3K/AKT/RAS signaling pathway is axis is impacted by the NP small EV proteome, which could promote ECM synthesis, cell growth and proliferation. Together, these processes underscore the essential role of the NP small EV proteome in sustaining NP cell function and NP niche homeostasis. ECM: Extracellular matrix; EPH: Ephrin receptor, ER: endoplasmic reticulum, ERK: extracellular signal-regulated kinase, MEK: mitogen-activated protein kinase, NP: nucleus pulposus, PDK1: phosphoinositide-dependent protein kinase 1, PPP: pentose phosphate pathway, PI3K/AKT: phosphoinositide 3-kinase/protein kinase B, RAF: rapidly accelerated fibrosarcoma, RHEB: RAS homolog enriched in brain, mTORC1: mammalian target of rapamycin complex 1, small EV: small extracellular vesicles, TSC1/2: tuberous sclerosis proteins 1 and 2. This illustration was created on Biorender. (www.biorender.com/).

https://doi.org/10.1371/journal.pone.0324179.g010

A potential for small EVs to engage with cell metabolism

Disc homeostasis depends on proper metabolism in the NP, which is linked to all cellular activities, and connected to various cellular dysfunctions, including degenerative changes such as IVDD [136]. An important energy source for NP cells is glucose, which can be used to generate ATP via glycolysis in anoxic conditions [137]. Degenerative changes in the CEPs or the AF could impact nutrient supply, resulting in cell stress and further progression of IVDD [136]. Cause-effect relationships between metabolic pathways and NP function remain under investigation [136,138]. Proteome profiling suggested a role of NP small EVs in glycolysis, gluconeogenesis, PPP and glutathione metabolism. Glutathione was previously considered as a potential treatment option for IVDD as it protects the IVD from oxidative stress [136,139]. Glycolytic enzymes were identified by small EV proteomic studies [140]. While these enzymes were not overrepresented among NP small EV proteins, we found several in our profiling data sets from fetal and adult NP parent cells, including LDHA, which has high affinity for pyruvate and preferentially converts pyruvate to lactate as an important step to restore the redox balance [141]. GAPDH, widely regarded as a housekeeping gene, fulfills diverse functions such as influencing cell fate by regulating cell death [142]. The contribution of functional glycolytic enzymes to a recipient cells’ energy and redox balance was suggested as one of the beneficial therapeutic outcomes of MSC small EV [140]. In addition to glycolytic enzymes TKT and G6PD were identified as part of the PPP. Their presence in NP small EVs suggests a form of metabolic coupling between parent and recipient cells possibly promoting various biosynthesis processes [136,143,144] and potentially equally beneficial than that of MSC small EV.

Housekeeping via proteosome delivery

NP cells are resilient in vitro. The proteasome pathway was linked to small EV proteins of bovine parent cells, existing sEV data, generally associated with NP small EVs, and also more abundant in NP small EVs over parent cells. Proteasomes play crucial roles in cellular proteostasis maintaining functional protein quality and removing protein waste [145,146]. Proteasome subunits were detected in EVs present in the growth media of mammalian cells and in body fluids [147162]. Studies suggested a parent cell specific encapsulation of proteasome subunits in vitro [148,162]. The exact mechanism by which proteasomes are targeted to EVs and their specific function within the EV context remains unclear, however, EVs facilitate cargo delivery to recipient cells through several mechanisms, including endocytosis, fusion to the plasma membrane, or phagocytosis [148,163,164]. Small EV proteasomes could maintain recipient cell proteostasis upon introduction into target cells. Alternatively, small EVs may also facilitate the export of proteasomes into the ECM to act on extracellular targets. For this, the content of the EVs should be emptied into the extracellular space. Studies have shown that lipid-degrading enzymes such as secretory phospholipase A2 and sphingomyelinase can dismantle EVs, liberating proteasomes into the extracellular environment [165]. Also inflammatory mediators could facilitate the release of lipid-degrading enzymes in response to cytokine activation, such as IL1, Interferon γ, and TNFα [166]. Potential therapeutic benefits of MSC small EVs with functional 20S proteasomes were demonstrated in a mouse model of myocardial ischemia, reducing the extent of damaged heart tissue and lowering levels of misfolded proteins [167]. Proteasomes in NP small EVs might therefore be instrumental for NP homeostasis and to alleviate inflammation.

Immunomodulation in an immune privileged environment

The healthy NP is considered immune privileged due to the physical blood-NP barrier established by the dense lamellar structure of the AF and the PG-rich CEPs, resulting in an absence of blood and lymphatic vessels in the healthy adult NP [124]. Nerves and vessels however are present in its periphery. Immune suppressive molecular factors like the cell surface death receptor Fas ligand (FASLG) were described for the NP and NP cells in vivo [168,169]. We could not detect FAS or FASLG in NP cells or NP small EVs generated in vitro by proteome analysis, however FAS and low level FASLG transcripts were previously detected in cultured NP cells, alongside transcripts for the migration inhibitory factor (MIF) [105].

Small EVs were previously associated with coagulation, immune modulation and the complement system [170,171]. Small EV proteins from all sources investigated here associated with pathways of the (innate) immune system and neutrophil degranulation amongst others. Neutrophils are known as the most abundant type of immune cell in the blood. A connection between IVDD and the infiltration of immune cells including different neutrophil subpopulations was described previously [172,173]. Neutrophils generate small EVs [174] and small EVs likely diffuse into NP tissue from the periphery [175]. However, neutrophils have a short lifespan in vitro and their research generally depends on freshly isolated cells from blood [176]. The cells cultured here, though of low passage number, were rinsed profoundly prior to exosome collection and unlikely contained neutrophils or their small EVs. The complement system represents a group of distinct plasma proteins as part of the innate immune response, essentially complementing antibodies with opsonization by acting through the classic, alternative or lectin pathway [177]. Complement proteins and related pathways were predominantly associated with more abundant NP small EV proteins and present in existing data sets. While NP cells are not a classic source for complement proteins, dysregulation of complement proteins was previously linked to inflammatory diseases such as IVDD, CEP lesions, osteo- and rheumatoid arthritis and a potential connection to neovascularization and innervation [177]. We found some complement proteins in NP small EVs and previously detected transcripts for several in NP cells, many at very low levels though [105]. The association of NP small EV proteins with the (innate) immune or the complement system could therefore be attributable to a serum corona, however, this alone does not provide sufficient explanation for a persistent association with above mentioned pathways after eliminating FBS associated proteins from the proteome data set. Other pathway associations such as focal adhesion and regulation of the cytoskeleton could also be an in vitro artefact, as NP cells are known to be very motile in 2D culture [178].

Receptor shuffling for niche homeostasis

Conserved during the evolution of domains and species, yet initially viewed as cellular debris, increasing evidence suggests that (small) EVs play a crucial role in the horizontal transfer of molecules between cells and as mediators of cell-cell communication, modulating mammalian cell signaling pathways such as PI3K/AKT, MAPK, AMPK, and cAMP which regulate a variety of cellular functions such as proliferation, survival, metabolism, and cell death [179182].

Vesicle mediated transport and membrane trafficking were among the top pathways identified for bovine small EV proteins and existing databases. Small EVs are likely essential for promoting intercellular communication in the microenvironment of the IVD, facilitating a flow of bioactive molecules among disc cells to preserve tissue homeostasis. Small EVs could be instrumental in maintaining an avascular and aneural environment in the healthy NP. Recent work demonstrated the theoretical possibility for small EVs to travel through the dense ECM meshwork in vivo [175] and the described bidirectional exchange of membrane components by multisized vesicles during NP cell and MSC coculture [183] supports small EVs as communication form. More recently, small EVs isolated from NC cell conditioned medium showed transforming properties and small EVs isolated from MSC had positive effects on NP cells [107,184,185]. With a size limited capacity of small EVs, membrane surface proteins might be put in place by the parent cell prior to vesicle release [186]. Secretory vesicles such as small EVs are an important source of cell receptors [187]. Small EVs can interact with their target cells through cell surface receptors and signaling cascades, fusion with the target cell or via endocytosis [188]. Several of the here identified NP small EV proteins associated with EPH-RTK signaling [189,190]. EPH-ephrin domain compositions and complex forward (receptor) and reverse (ligand) signaling events are reviewed in great detail elsewhere [191193]. This signaling pathway is known for its role during embryonic development including the partitioning of the dorsal mesoderm into NC and paraxial mesoderm [194196], and its’ implication with tissue homeostasis and repair in the adult, maintaining skeletal, hematopoietic and neuronal integrity [192,197]. EPH-ephrin interaction typically requires cell-cell contact as receptor and ligand are membrane bound, allowing for uni- or bidirectional signaling [192]. Signaling robustness and strength is correlated with the extend of cluster formation [192,198]. EPH receptor and ephrin ligand transcripts were detected in NP cells in vitro [105,190], however only EPH receptors were identified in the NP small EV proteome. Endocytosis of EPH-ephrin complexes as a mean to regulate signaling was described [199]. Though EPH-ephrin signaling in the adult lacks behind its understanding during embryogenesis, it could be relevant for IVD homeostasis that this pathway is reestablished to control stem cell niches; cell homeostasis; tissue boundary formation; cell proliferation, differentiation and migration; metabolism and the cytoskeleton with an antiproliferative effect on the neural stem cell niche, inhibiting neurogenesis beyond just impacting axon guidance as reviewed in [192,197]. Furthermore EPH-ephrin, NOTCH and VEGF signaling play important roles in angiogenesis and arteriovenous patterning through the control of cell fate decisions [200]. Here we found an association between proteins of small EVs from NP parent cells and EPH-receptors. We therefore propose the following potential mechanisms based on qualitative and quantitative small EV proteomics data generated here as well as previous RNA transcript analysis in comparable 2D culture conditions [105] (S8 Fig): A) “Down-tuning” of signals in NP parent cells: Studies have suggested a function for EVs in removing undesired compounds, as such contributing to cellular homeostasis by protecting cells [201,202]. Packaging EPH receptors into small EV membranes could remove them from NP parent cells, preventing non-ligand induced forward signaling amidst plentiful growth factors in culture medium. This could prevent excessive proliferation [190,191]. B) “Amplifying” signals in target cells: On the contrary, shuffling EPH receptors to NP target cells could intensify a downstream forward signaling response in target cells. C) “Avoiding consequences” small EVs could circumvent an otherwise required close cell contact and enable a unique form of long-range communication still based on membrane contact by inducing reverse signaling in target cells without forward signaling consequence in the parent cell [198]. Future in vivo validation might favor or exclude one of the mechanisms.

In addition to EPH receptors, we identified many components of the RAS signaling cascades. It was suggested that RAS downstream signaling is important for small EV biogenesis, release, maintenance and signaling. RAS engagement in RTK signaling can lead to cell fate decisions between survival and death, essentially through the activation of the ERK/MAPK or PI3K/AKT pathways [193,203,204]. Other RTKs were identified as well, such as VEGFR2 which can activate downstream PI3K/AKT and mammalian target of rapamycin (MTOR) signaling, impacting angiogenesis via cell proliferation and survival [205]. The RTK epidermal growth factor receptor (ERBB1) downstream pathways can initiate the mitogen-activated protein kinase (MAPK) cascade or PI3K/AKT signaling [206]. The PI3K/AKT pathway, can influence cell proliferation, apoptosis, autophagy, and differentiation under physiological and pathological conditions by interacting with a number of downstream target proteins, including MTOR and Forkhead box O1 (FOXO1) [63,207]. Also triggered by RAS signaling events, the MAPK/extracellular signal-regulated kinase (ERK) pathway is an essential intracellular signal transduction pathway that is critical in maintaining IVD homeostasis [208212].

Maintaining ECM homeostasis

Harnessing “stemness” is an intriguing approach taken by the field of regenerative medicine to treat degenerative diseases or tissue loss. This can include the transplantation of transdifferentiated somatic cells, induced pluripotent stem cells or embryonic stem cells, all though posing a risk of tumorigenesis. Additionally, some cell types are deemed uneconomical on an individualized basis, are not fully understood in their differentiation potential, or face ethical concerns [213216]. Autologous or allogeneic MSC gained popularity since their less-tumorigenic multipotent potential might be directed into the appropriate cell type via endogenous cues from the recipient tissue. However, transplanted stem cells often face delivery and survival challenges, especially in tissues with a naturally harsh microniche environment such as the IVD. MSC likely signal to resident stem cell populations via small EVs to kick-start refurbishment [185,217219]. Given the adaption of NP cells to their niche, healthy NP parent cells seem a logic source for small EV production. Since no direct association of NP small EV proteins with stemness was identified, maintenance of cell and tissue homeostasis in the NP could be their main contribution.

During IVDD progression, not only is the expression of pro-inflammatory markers and ECM degrading enzymes noted, but also the exhaustion of progenitor cells. At the same time ECM synthesis reflected by structural collagens, Acan and small PGs declines as complex events of cellular senescence and regulated cell death rise [9,10,12,220226]. ECM components like fibronectin connect with cell adhesion receptors and integrins to facilitate cell-cell and cell-matrix interactions, which have an impact on cell differentiation, proliferation, and function [227232]. Integrin receptors too possess unique bidirectional signaling properties, coordinating extracellular events such as binding with laminin, or stiffness of the ECM with intracellular changes such as activation of the PI3K/AKT signaling pathway [233247]. EV associated fibronectin plays a role in maintaining pluripotency and stemness of embryonic stem cells, while fibronectin fragments increase with IVDD progression [233,248,249]. These fragments may contribute to IVDD by inducing ECM degradation while suppressing PG synthesis [168,248,250253]. Moreover, fibronectin is a significant heparan sulfate ligand mediating cell-small EV interactions and heparan sulfate proteoglycan 2 (HSPG2), a more abundant NP small EV protein, facilitates small EV uptake by cells [235].

Through interactions with fibronectin, laminin and other ECM molecules, collagen VI (COLVI) influences cell-ECM interactions, thereby modulating cellular behavior and tissue function [254256]. COLVI which was more abundant in NP small EVs is a multifaceted protein associated with ECM organization, nervous system development, focal adhesion and PI3K/AKT-MTOR signaling, maintaining tissue and cell homeostasis [257]. It provides tensile strength and structural integrity to the ECM, and is involved in regulating apoptosis, reducing oxidative stress, and maintaining cell stemness [258]. By modulating signaling cascades involved in programmed cell death, COLVI maintains tissue integrity and function [257,259]. Its antioxidative properties scavenge reactive oxygen species (ROS), thereby protecting cells from oxidative damage [260,261]. In stem cell niches, COLVI maintains stemness by providing a supportive microenvironment. This maintains stem cell populations and supports tissue regeneration processes [257,259]. By modulating signaling pathways involved in cell cycle regulation and ECM production, COLVI promotes tissue homeostasis [259,262].

Current limitations and outlook

We identified a considerable overlap in small EV proteins and function between our and existing data, supporting our approach. While proteome profiling of IVD derived small EVs by state-of-the-art mass spectrometry enabled the suggestion of proteome related molecular mechanisms behind cell and tissue homeostasis in this unique organ, small EV nucleic acid cargo was not assessed here. It remains to be elucidated which bioactive molecule class takes the center role in small EV mediated cell-cell communication. Further work and technology development will hopefully also provide insight into stoichiometric relationships between number of molecules per small EV surface or volume and minimum numbers of small EVs triggering phenotypic effects.

Conclusions

Small EV research in the IVD recently gained momentum due to advantages over cell based regenerative therapies. This work focused on the proteomic profiling of small EVs, especially bovine NP small EVs. Under standard culture conditions, we found no clear indication that the here identified NP small EV proteins mobilized progenitor cells other than through the RAS signaling cascade; neither is there reason to believe they initiated senescence. Instead, the NP small EV proteome appeared to mediate NP niche and ECM homeostasis including cell fate decisions. We suggest that small EVs from NP parent cells contribute to NP cell metabolism and NP niche homeostasis beyond MSC by maintaining the unique avascular, aneural and immune privileged environment through anti-angiogenic and axon growth inhibitory processes. We believe that in the challenging niche environment, NP small EVs provide resources for an effective redox, energy and pH balance through the delivery of key metabolic enzymes. The association with EPH-RTK signaling further suggests that NP small EVs could regulate cell surface membrane receptor densities and therefore impact on the transduction of extracellular signals to the NP cell. Small EVs from NP parent cells might also deliver proteasome subunits, which could be of great importance in regulating crucial signaling cascades such as RUNX, NOTCH4, P53, PTEN, Hedgehog and others.

Supporting information

S1 Fig. Example of RNA in situ hybridization for some ECM markers.

IVD tissue (top panels) and derived cell lines (bottom panels) were investigated for transcripts. Mallory’s tetrachrome stain was used in IVD tissue for histological reference. Bovine digoxygenin labeled RNA probes were generated through reverse transcription from polymerase chain reaction generated templates, employing the T7 promoter for the antisense probe. Collagen I (Col1a1; F:GGGGCAAGACAGTGATCGAA/ R: TTGGCTTTTCGGGGGTTTCA (229 bp)), collagen II (Col2a1; F:TCACAGAAGACCTCCCGTCT/ R:TCACAGAAGACCTCCCGTCT (561 bp)) and collagen VI (Col6a1; F: ACATCACCAAACGCTTTGCCA/ R: GGACAGAGAACCAGGTGCCA (821 bp)) are shown as example. Scale bar reflects 25μm. Red arrows indicate negative and green arrows indicate positive cells for gene expression. AF: annulus fibrosus, F: forward primer, IVD: intervertebral disc, NP: nucleus pulposus, R: reverse primer.

https://doi.org/10.1371/journal.pone.0324179.s001

(TIF)

S2 Fig. Original uncropped Western blot membranes.

Focus areas for CD63 and TSG101 are indicated by a blue rectangle. 2k: DUC fraction containing debris and larger EVs; 10k: DUC fraction containing larger EVs; 130k pre: DUC small EV fraction before PBS wash; 130K post: DUC small EV fraction after PBS wash; CD63: Cell surface protein of the tetraspanin family; Hi-FBS: small EV fraction of heat inactivated fetal bovine serum used for cell culture prior to exosome harvest serving as small EV positive control. HRP: horseradish peroxidase; NP: nucleus pulposus; p5: passage 5 parent cell; M: New England Biolabs (NEB) marker; TSG101: Tumor susceptibility gene 101.

https://doi.org/10.1371/journal.pone.0324179.s002

(TIF)

S3 Fig. Functional enrichment analysis of autologous cells.

A) Biological processes (BP); (B) molecular functions (MF) and (C) cellular components (CC) associated with 102 shared small EVs proteins from NP, AF and FAT parent cell lines; D) Biological processes (BP); (E) molecular functions (MF) and (F) cellular components (CC) associated with 156 small EV proteins from NP parent cells. AF: Annulus fibrosus; FAT: Adipose tissue; NP: Nucleus pulposus.

https://doi.org/10.1371/journal.pone.0324179.s003

(TIF)

S4 Fig. Functional enrichment analysis of adult and fetal NP and UCMSC cells.

A) Biological processes (BP); (B) molecular functions (MF) and (C) cellular components (CC) associated with 206 shared small EV proteins from adult NP, fetal NP, and UCMSC parent cells. NP: Nucleus pulposus; UCMSCs: Umbilical cord mesenchymal stem cells.

https://doi.org/10.1371/journal.pone.0324179.s004

(TIF)

S5 Fig. Quantitative functional enrichment analysis of 141 proteins more abundant in NP small EVs as compared to their parent cells.

A) Biological Processes (BP), B) Molecular Function (MF), C) Cellular Component (CC). NP: Nucleus pulposus.

https://doi.org/10.1371/journal.pone.0324179.s005

(TIF)

S6 Fig. Venn diagrams identifying shared ToppFun pathways for the top 200 pathways associated with the different small EV protein sources.

AF: Annulus fibrosus; FAT: Adipose tissue; NP: Nucleus pulposus; or: overrepresented; UCMSC: Umbilical cord mesenchymal stem cell.

https://doi.org/10.1371/journal.pone.0324179.s006

(TIF)

S7 Fig. Comparison of fetal bovine serum proteins and small EV proteins by various NP parent cell sources.

A) Comparison of small EV proteins from different NP parent cell sources with proteins in fetal bovine serum used for culturing. B) KEGG pathway analysis in DAVID for remaining NP small EV proteins from all sources combined and C) from more abundant NP small EV protein safter serum protein exclusion. D) ToppFun pathway analysis for remaining NP small EV proteins from all sources combined and E) from more abundant NP small EV proteins after serum protein exclusion.

https://doi.org/10.1371/journal.pone.0324179.s007

(TIF)

S8 Fig. Simplified schematic of complex EPH-ephrin signaling events.

EPH: Ephrin receptor; EFN: ephrin ligand; R: receptor; L: ligand.

https://doi.org/10.1371/journal.pone.0324179.s008

(TIF)

S1 Table. Protein Concentration of small EV Fractions.

NP: nucleus pulposus; TT32, TT33, TT39: cell lines; p: passage number.

https://doi.org/10.1371/journal.pone.0324179.s009

(XLSX)

S2 Table. Identified small EV proteins.

AF: annulus fibrosus; FAT: adipose tissue; NP: nucleus pulposus.

https://doi.org/10.1371/journal.pone.0324179.s010

(XLSX)

S3 Table. Averaged TPM values for RNA sequencing data on NP, AF and FAT cells based on two (FAT) or three (AF,NP) replicates per cell line.

The data generated under comparable conditions and depostited in NCBI GEO (https://www.ncbi.nlm.nih.gov/geo/), accession number GSE216377. TMP: Transcripts per million.

https://doi.org/10.1371/journal.pone.0324179.s011

(XLSX)

S4 Table. ToppFun functional enrichment analysis for pathways associated with bovine small EV proteins contained in ExoCarta and/or Vesiclepedia datasets showing a selection of the top 200 pathways.

https://doi.org/10.1371/journal.pone.0324179.s012

(XLSX)

S5 Table. Functional enrichment analysis (DAVID) comparing small EV proteins of autologous bovine NP, AF, and FAT parent cells.

AF: Annulus fibrosus; bta: Bos taurus; cAMP: Cyclic adenosine monophosphate; DAVID: Database for annotation, visualization, and integrated discovery; ECM: Extracellular matrix; FAT: Subcutaneous adipose tissue; GO: Gene ontology; KEGG: Kyoto encyclopedia of genes and genomes; FAT: Subcutaneous adipose tissue; MAPK: Mitogen-activated protein kinase; NP: Nucleus pulposus.

https://doi.org/10.1371/journal.pone.0324179.s013

(XLSX)

S6 Table. ToppFun analysis of shared pathways between small EV proteins from autologous bovine NP, AF, and FAT parent cells.

AF: Annulus fibrosus; FAT: Subcutaneous adipose tissue; GO: gene ontology; bta: Bos taurus; cAMP: Cyclic adenosine monophosphate; ECM: Extracellular matrix; KEGG: Kyoto Encyclopedia of Genes and Genomes; FAT: Subcutaneous adipose tissue; MAPK: Mitogen-activated protein kinase; NP: Nucleus pulposus. *denotes 20 pathways detected for all investigated bovine parent cells in this study; #denotes 9 pathways detected for all investigated small EV proteins in this study.

https://doi.org/10.1371/journal.pone.0324179.s014

(XLSX)

S7 Table. Functional enrichment analysis (DAVID) comparing small EV proteins of adult and fetal NP cells with UCMSC cells of shared exosome proteins of NP, fetal NP, and UCMSC cells.

bta: Bos taurus; DAVID: Database for annotation, visualization, and integrated discovery; FAT: Adipose tissue; KEGG: Kyoto encyclopedia of genes and genomes; NP: Nucleus pulposus; UCMSC: Umbilical cord mesenchymal stem cells.

https://doi.org/10.1371/journal.pone.0324179.s015

(XLSX)

S8 Table. ToppFun analysis of shared pathways between small EV proteins from bovine adult and fetal NP, and UCMSC parent cells.

bta: Bos taurus; ECM: Extracellular matrix; KEGG: Kyoto Encyclopedia of Genes and Genomes; NP: Nucleus pulposus. *denotes 20 pathways detected for all investigated bovine parent cells in this study; #denotes 9 pathways detected for all investigated small EV proteins in this study.

https://doi.org/10.1371/journal.pone.0324179.s016

(XLSX)

S9 Table. Functional enrichment analysis (DAVID) after quantitative analysis of NP small EV proteins comparing NP small EV and parent cells.

bta: Bos taurus; DAVID: Database for annotation, visualization, and integrated discovery; GO: Gene ontology; KEGG: Kyoto encyclopedia of genes and genomes; NP: Nucleus pulposus.

https://doi.org/10.1371/journal.pone.0324179.s017

(XLSX)

S10 Table. ToppFun pathway analysis of more or less abundant NP small EV proteins.

https://doi.org/10.1371/journal.pone.0324179.s018

(XLSX)

S11 Table. Comparison of top 200 results of ToppFun pathways for each small EV source identifies nine pathways shared by all sources.

AF: Annulus fibrosus; NP: Nucleus pulposus; UCMSC: Umbilical cord mesenchymal stem cells.

https://doi.org/10.1371/journal.pone.0324179.s019

(XLSX)

S12 Table. ToppFun pathway analysis for FBS proteins and all NP small EV proteins after FBS protein removal.

FBS: Fetal bovine serum; NP: Nucleus pulposus.

https://doi.org/10.1371/journal.pone.0324179.s020

(XLSX)

Acknowledgments

We are grateful to Shane Rogers for access to an ultracentrifuge, Daniel Andreescu for access to DLS, Hubert Bilan for expertise in SEM, the Darie lab for preliminary studies (all Clarkson University), Peter Braun of Woodcrest Dairy (Lisbon, NY), Tritown Meat Packing (Brasher Falls, NY) and Willard & Sons (Heuvelton, NY, USA) for bovine specimens. We especially thank the Interdisciplinary Center for Biotechnology Research (ICBR, RRID: SCR_01951) for their invaluable support.

For gene/protein symbol abbreviation please visit gene cards (https://www.genecards.org) or the National Center of Biotechnology Information (NCBI) (https://www.ncbi.nlm.nih.gov)

References

  1. 1. Casiano VE, Sarwan G, Dydyk AM, Varacallo M. Back Pain. StatPearls. Treasure Island (FL): StatPearls Publishing; 2023. Available from: http://www.ncbi.nlm.nih.gov/books/NBK538173/
  2. 2. Freburger JK, Holmes GM, Agans RP, Jackman AM, Darter JD, Wallace AS, et al. The rising prevalence of chronic low back pain. Arch Intern Med. 2009;169(3):251–8. pmid:19204216
  3. 3. Gatchel RJ. The continuing and growing epidemic of chronic low back pain. Healthcare (Basel). 2015;3(3):838–45. pmid:27417800
  4. 4. Taylor T, Ghosh P, Bushell G. The contribution of the intervertebral disk to the scoliotic deformity. Clin Orthop Relat Res. 1981:79–90.
  5. 5. Desmoulin GT, Pradhan V, Milner TE. Mechanical aspects of intervertebral disc injury and implications on biomechanics. Spine (Phila Pa 1976). 2020;45(8):E457–64. pmid:31651681
  6. 6. Samanta A, Lufkin T, Kraus P. Intervertebral disc degeneration-Current therapeutic options and challenges. Front Public Health. 2023;11:1156749. pmid:37483952
  7. 7. Whatley BR, Wen X. Intervertebral disc (IVD): structure, degeneration, repair and regeneration. Mater Sci Eng C. 2012;32(2):61–77.
  8. 8. Xin J, Wang Y, Zheng Z, Wang S, Na S, Zhang S. Treatment of intervertebral disc degeneration. Orthop Surg. 2022;14(7):1271–80. pmid:35486489
  9. 9. Bayliss MT, Johnstone B, O’Brien JP. 1988 Volvo award in basic science. Proteoglycan synthesis in the human intervertebral disc. Variation with age, region and pathology. Spine (Phila Pa 1976). 1988;13(9):972–81. pmid:3206304
  10. 10. Bibby SR, Jones DA, Lee RB, Yu J, Urban JPG. The pathophysiology of the intervertebral disc. Joint Bone Spine. 2001;68(6):537–42. pmid:11808995
  11. 11. Eyre DR. Biochemistry of the intervertebral disc. Int Rev Connect Tissue Res. 1979;8:227–91. pmid:389859
  12. 12. Humzah MD, Soames RW. Human intervertebral disc: structure and function. Anat Rec. 1988;220(4):337–56. pmid:3289416
  13. 13. Murphy K, Lufkin T, Kraus P. Development and degeneration of the intervertebral disc-insights from across species. Vet Sci. 2023;10(9):540. pmid:37756062
  14. 14. Oegema TR Jr. Biochemistry of the intervertebral disc. Clin Sports Med. 1993;12(3):419–38.
  15. 15. Shapiro IM, Risbud MV. Introduction to the structure, function, and comparative anatomy of the vertebrae and the intervertebral disc. In: Shapiro IM, Risbud MV, editors. The intervertebral disc: molecular and structural studies of the disc in health and disease. Vienna: Springer; 2014. p. 3–15. https://doi.org/10.1007/978-3-7091-1535-0_1
  16. 16. Sivakamasundari V, Lufkin T. Stemming the degeneration: IVD stem cells and stem cell regenerative therapy for degenerative disc disease. Adv Stem Cells. 2013;2013:724547. pmid:23951558
  17. 17. Urban JPG, Smith S, Fairbank JCT. Nutrition of the intervertebral disc. Spine (Phila Pa 1976). 2004;29(23):2700–9. pmid:15564919
  18. 18. Nachemson A, Lewin T, Maroudas A, Freeman MA. In vitro diffusion of dye through the end-plates and the annulus fibrosus of human lumbar inter-vertebral discs. Acta Orthop Scand. 1970;41(6):589–607. pmid:5516549
  19. 19. Adams MA, Roughley PJ. What is intervertebral disc degeneration, and what causes it? Spine (Phila Pa 1976). 2006;31(18):2151–61. pmid:16915105
  20. 20. Erwin WM, Hood KE. The cellular and molecular biology of the intervertebral disc: a clinician’s primer. J Can Chiropr Assoc. 2014;58(3):246–57. pmid:25202152
  21. 21. Errington RJ, Puustjarvi K, White IR, Roberts S, Urban JP. Characterisation of cytoplasm-filled processes in cells of the intervertebral disc. J Anat. 1998;192 ( Pt 3)(Pt 3):369–78. pmid:9688503
  22. 22. Empere M, Wang X, Prein C, Aspberg A, Moser M, Oohashi T, et al. Aggrecan governs intervertebral discs development by providing critical mechanical cues of the extracellular matrix. Front Bioeng Biotechnol. 2023;11:1128587. pmid:36937743
  23. 23. O’Halloran DM, Pandit AS. Tissue-engineering approach to regenerating the intervertebral disc. Tissue Eng. 2007;13(8):1927–54. pmid:17518718
  24. 24. Bach FC, Poramba-Liyanage DW, Riemers FM, Guicheux J, Camus A, Iatridis JC, et al. Notochordal cell-based treatment strategies and their potential in intervertebral disc regeneration. Front Cell Dev Biol. 2022;9:780749. pmid:35359916
  25. 25. Choi K-S, Cohn MJ, Harfe BD. Identification of nucleus pulposus precursor cells and notochordal remnants in the mouse: implications for disk degeneration and chordoma formation. Dev Dyn. 2008;237(12):3953–8. pmid:19035356
  26. 26. Butler WF. Comparative anatomy and development of the mammalian disc. In: Biology of invertebral disc. CRC Press; 1988.
  27. 27. Hendry NG. The hydration of the nucleus pulposus and its relation to intervertebral disc derangement. J Bone Joint Surg Br. 1958;40-B(1):132–44. pmid:13513662
  28. 28. Choi K-S, Lee C, Harfe BD. Sonic hedgehog in the notochord is sufficient for patterning of the intervertebral discs. Mech Dev. 2012;129(9–12):255–62. pmid:22841806
  29. 29. Choi K-S, Harfe BD. Hedgehog signaling is required for formation of the notochord sheath and patterning of nuclei pulposi within the intervertebral discs. Proc Natl Acad Sci U S A. 2011;108(23):9484–9. pmid:21606373
  30. 30. Christ B, Wilting J. From somites to vertebral column. Ann Anat. 1992;174(1):23–32. pmid:1605355
  31. 31. Kraus P, Yerden R, Kocsis V, Lufkin T. RNA in situ hybridization characterization of non-enzymatic derived bovine intervertebral disc cell lineages suggests progenitor cell potential. Acta Histochem. 2017;119(2):150–60. pmid:28063600
  32. 32. Lawson L, Harfe BD. Notochord to nucleus pulposus transition. Curr Osteoporos Rep. 2015;13(5):336–41. pmid:26231139
  33. 33. McCann MR, Séguin CA. Notochord cells in intervertebral disc development and degeneration. J Dev Biol. 2016;4(1):3. pmid:27252900
  34. 34. McCann MR, Tamplin OJ, Rossant J, Séguin CA. Tracing notochord-derived cells using a Noto-cre mouse: implications for intervertebral disc development. Dis Model Mech. 2012;5(1):73–82. pmid:22028328
  35. 35. Trout JJ, Buckwalter JA, Moore KC, Landas SK. Ultrastructure of the human intervertebral disc. I. Changes in notochordal cells with age. Tissue Cell. 1982;14(2):359–69. pmid:7202266
  36. 36. Urban JPG, Roberts S. Degeneration of the intervertebral disc. Arthritis Res Ther. 2003;5(3):120–30. pmid:12723977
  37. 37. Vujovic S, Henderson S, Presneau N, Odell E, Jacques TS, Tirabosco R, et al. Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas. J Pathol. 2006;209(2):157–65. pmid:16538613
  38. 38. Urban JPG, Roberts S, Ralphs JR. The nucleus of the intervertebral disc from development to degeneration. Am Zool. 2000;40(1):53–061.
  39. 39. Le Maitre CL, Pockert A, Buttle DJ, Freemont AJ, Hoyland JA. Matrix synthesis and degradation in human intervertebral disc degeneration. Biochem Soc Trans. 2007;35(Pt 4):652–5. pmid:17635113
  40. 40. Sakai D, Nakamura Y, Nakai T, Mishima T, Kato S, Grad S, et al. Exhaustion of nucleus pulposus progenitor cells with ageing and degeneration of the intervertebral disc. Nat Commun. 2012;3:1264. pmid:23232394
  41. 41. Urban JP, Holm S, Maroudas A, Nachemson A. Nutrition of the intervertebral disk. An in vivo study of solute transport. Clin Orthop Relat Res. 1977:101–14.
  42. 42. Beckstein JC, Sen S, Schaer TP, Vresilovic EJ, Elliott DM. Comparison of animal discs used in disc research to human lumbar disc: axial compression mechanics and glycosaminoglycan content. Spine (Phila Pa 1976). 2008;33(6):E166-73. pmid:18344845
  43. 43. Bonnaire FC, Danalache M, Sigwart VA, Breuer W, Rolauffs B, Hofmann UK. The intervertebral disc from embryonic development to disc degeneration: insights into spatial cellular organization. Spine J. 2021;21(8):1387–98. pmid:33872805
  44. 44. Minogue BM, Richardson SM, Zeef LA, Freemont AJ, Hoyland JA. Transcriptional profiling of bovine intervertebral disc cells: implications for identification of normal and degenerate human intervertebral disc cell phenotypes. Arthritis Res Ther. 2010;12(1):R22. pmid:20149220
  45. 45. O’Connell GD, Vresilovic EJ, Elliott DM. Comparison of animals used in disc research to human lumbar disc geometry. Spine (Phila Pa 1976). 2007;32(3):328–33. pmid:17268264
  46. 46. Calió M, Gantenbein B, Egli M, Poveda L, Ille F. The cellular composition of bovine coccygeal intervertebral discs: a comprehensive single-cell RNAseq analysis. Int J Mol Sci. 2021;22(9):4917. pmid:34066404
  47. 47. Cherif H, Mannarino M, Pacis AS, Ragoussis J, Rabau O, Ouellet JA, et al. Single-cell RNA-seq analysis of cells from degenerating and non-degenerating intervertebral discs from the same individual reveals new biomarkers for intervertebral disc degeneration. Int J Mol Sci. 2022;23(7):3993. pmid:35409356
  48. 48. Gan Y, He J, Zhu J, Xu Z, Wang Z, Yan J, et al. Spatially defined single-cell transcriptional profiling characterizes diverse chondrocyte subtypes and nucleus pulposus progenitors in human intervertebral discs. Bone Res. 2021;9(1):37. pmid:34400611
  49. 49. Han S, Zhang Y, Zhang X, Zhang H, Meng S, Kong M, et al. Single-cell RNA sequencing of the nucleus pulposus reveals chondrocyte differentiation and regulation in intervertebral disc degeneration. Front Cell Dev Biol. 2022;10:824771. pmid:35265617
  50. 50. Ling Z, Liu Y, Wang Z, Zhang Z, Chen B, Yang J, et al. Single-cell RNA-seq analysis reveals macrophage involved in the progression of human intervertebral disc degeneration. Front Cell Dev Biol. 2022;9:833420. pmid:35295968
  51. 51. Panebianco CJ, Dave A, Charytonowicz D, Sebra R, Iatridis JC. Single-cell RNA-sequencing atlas of bovine caudal intervertebral discs: discovery of heterogeneous cell populations with distinct roles in homeostasis. FASEB J. 2021;35(11):e21919. pmid:34591994
  52. 52. Rodrigues-Pinto R, Ward L, Humphreys M, Zeef LAH, Berry A, Hanley KP, et al. Human notochordal cell transcriptome unveils potential regulators of cell function in the developing intervertebral disc. Sci Rep. 2018;8(1):12866. pmid:30150762
  53. 53. Rohanifar M, Clayton SW, Easson GWD, Patil DS, Lee F, Jing L, et al. Single cell RNA-sequence analyses reveal uniquely expressed genes and heterogeneous immune cell involvement in the rat model of intervertebral disc degeneration. Appl Sci (Basel). 2022;12(16):8244. pmid:36451894
  54. 54. Wang J, Huang Y, Huang L, Shi K, Wang J, Zhu C, et al. Novel biomarkers of intervertebral disc cells and evidence of stem cells in the intervertebral disc. Osteoarthritis Cartilage. 2021;29(3):389–401. pmid:33338640
  55. 55. Zhang Y, Han S, Kong M, Tu Q, Zhang L, Ma X. Single-cell RNA-seq analysis identifies unique chondrocyte subsets and reveals involvement of ferroptosis in human intervertebral disc degeneration. Osteoarthritis Cartilage. 2021;29(9):1324–34. pmid:34242803
  56. 56. Kraus P, Lufkin T. Implications for a stem cell regenerative medicine based approach to human intervertebral disk degeneration. Front Cell Dev Biol. 2017;5:17. pmid:28326305
  57. 57. Li K, Kapper D, Youngs B, Kocsis V, Mondal S, Kraus P, et al. Potential biomarkers of the mature intervertebral disc identified at the single cell level. J Anat. 2019;234(1):16–32. pmid:30450595
  58. 58. Vedicherla S, Buckley CT. Cell-based therapies for intervertebral disc and cartilage regeneration- current concepts, parallels, and perspectives. J Orthop Res. 2017;35(1):8–22. pmid:27104885
  59. 59. Xia Y, Yang R, Hou Y, Wang H, Li Y, Zhu J, et al. Application of mesenchymal stem cell-derived exosomes from different sources in intervertebral disc degeneration. Front Bioeng Biotechnol. 2022;10:1019437. pmid:36277386
  60. 60. Grunhagen T, Shirazi-Adl A, Fairbank JCT, Urban JPG. Intervertebral disk nutrition: a review of factors influencing concentrations of nutrients and metabolites. Orthop Clin North Am. 2011;42(4):465–77, vii. pmid:21944584
  61. 61. Liang C-Z, Li H, Tao Y-Q, Zhou X-P, Yang Z-R, Li F-C, et al. The relationship between low pH in intervertebral discs and low back pain: a systematic review. Arch Med Sci. 2012;8(6):952–6. pmid:23319966
  62. 62. Sakai D, Schol J. Cell therapy for intervertebral disc repair: clinical perspective. J Orthop Translat. 2017;9:8–18. pmid:29662795
  63. 63. Tian D, Liu J, Chen L, Zhu B, Jing J. The protective effects of PI3K/Akt pathway on human nucleus pulposus mesenchymal stem cells against hypoxia and nutrition deficiency. J Orthop Surg Res. 2020;15(1):29. pmid:31992313
  64. 64. Wuertz K, Godburn K, Neidlinger-Wilke C, Urban J, Iatridis JC. Behavior of mesenchymal stem cells in the chemical microenvironment of the intervertebral disc. Spine (Phila Pa 1976). 2008;33(17):1843–9. pmid:18670337
  65. 65. Cargnoni A, Papait A, Masserdotti A, Pasotti A, Stefani FR, Silini AR, et al. Extracellular vesicles from perinatal cells for anti-inflammatory therapy. Front Bioeng Biotechnol. 2021;9:637737. pmid:33614619
  66. 66. Fatima F, Ekstrom K, Nazarenko I, Maugeri M, Valadi H, Hill AF, et al. Non-coding RNAs in mesenchymal stem cell-derived extracellular vesicles: deciphering regulatory roles in stem cell potency, inflammatory resolve, and tissue regeneration. Front Genet. 2017;8:161. pmid:29123544
  67. 67. Camussi G, Deregibus MC, Bruno S, Cantaluppi V, Biancone L. Exosomes/microvesicles as a mechanism of cell-to-cell communication. Kidney Int. 2010;78(9):838–48. pmid:20703216
  68. 68. Binch A, Cross A, Le Maitre C. The regulation of nerve and blood vessel ingrowth in aneural and avascular intervertebral disc and articular cartilage. OA Arthritis. 2014;2:4.
  69. 69. Binch ALA, Cole AA, Breakwell LM, Michael ALR, Chiverton N, Creemers LB, et al. Nerves are more abundant than blood vessels in the degenerate human intervertebral disc. Arthritis Res Ther. 2015;17:370. pmid:26695177
  70. 70. Zhang Y, Bi J, Huang J, Tang Y, Du S, Li P. Exosome: a review of its classification, isolation techniques, storage, diagnostic and targeted therapy applications. Int J Nanomedicine. 2020;15:6917–34. pmid:33061359
  71. 71. Bang C, Thum T. Exosomes: new players in cell-cell communication. Int J Biochem Cell Biol. 2012;44(11):2060–4. pmid:22903023
  72. 72. Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367(6478):eaau6977. pmid:32029601
  73. 73. Nazimek K, Bryniarski K, Santocki M, Ptak W. Exosomes as mediators of intercellular communication: clinical implications. Pol Arch Med Wewn. 2015;125(5):370–80. pmid:25978300
  74. 74. Pitt JM, Kroemer G, Zitvogel L. Extracellular vesicles: masters of intercellular communication and potential clinical interventions. J Clin Invest. 2016;126(4):1139–43. pmid:27035805
  75. 75. Kraus P, Samanta A, Lufkin S, Lufkin T. Stem cells in intervertebral disc regeneration-more talk than action? Biocell. 2021;46(6):893–8. pmid:34966192
  76. 76. Welsh JA, Goberdhan DCI, O’Driscoll L, Buzas EI, Blenkiron C, Bussolati B, et al. Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches. J Extracell Vesicles. 2024;13(2):e12404. pmid:38326288
  77. 77. Kowal J, Arras G, Colombo M, Jouve M, Morath JP, Primdal-Bengtson B, et al. Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes. Proc Natl Acad Sci U S A. 2016;113(8):E968-77. pmid:26858453
  78. 78. Ruivo CF, Adem B, Silva M, Melo SA. The biology of cancer exosomes: insights and new perspectives. Cancer Res. 2017;77(23):6480–8. pmid:29162616
  79. 79. Edgar JR. Q&A: What are exosomes, exactly? BMC Biol. 2016;14:46. pmid:27296830
  80. 80. Chen Y, Tang Y, Fan G-C, Duan DD. Extracellular vesicles as novel biomarkers and pharmaceutic targets of diseases. Acta Pharmacol Sin. 2018;39(4):499–500. pmid:29606702
  81. 81. Jalalian SH, Ramezani M, Jalalian SA, Abnous K, Taghdisi SM. Exosomes, new biomarkers in early cancer detection. Anal Biochem. 2019;571:1–13. pmid:30776327
  82. 82. LeBleu VS, Kalluri R. Exosomes as a multicomponent biomarker platform in cancer. Trends Cancer. 2020;6(9):767–74. pmid:32307267
  83. 83. Makler A, Asghar W. Exosomal biomarkers for cancer diagnosis and patient monitoring. Expert Rev Mol Diagn. 2020;20(4):387–400. pmid:32067543
  84. 84. DiStefano TJ, Vaso K, Danias G, Chionuma HN, Weiser JR, Iatridis JC. Extracellular vesicles as an emerging treatment option for intervertebral disc degeneration: therapeutic potential, translational pathways, and regulatory considerations. Adv Healthc Mater. 2022;11(5):e2100596. pmid:34297485
  85. 85. Li Q-W, Guo R-C, Wu Z-M, Shen C-L. Potential use of extracellular vesicles in the treatment of intervertebral disc degeneration. Tissue Eng Part C Methods. 2024;30(2):73–84. pmid:37930732
  86. 86. Krut Z, Pelled G, Gazit D, Gazit Z. Stem cells and exosomes: new therapies for intervertebral disc degeneration. Cells. 2021;10(9):2241. pmid:34571890
  87. 87. Khan AN, Jacobsen HE, Khan J, Filippi CG, Levine M, Lehman RA Jr, et al. Inflammatory biomarkers of low back pain and disc degeneration: a review. Ann N Y Acad Sci. 2017;1410(1):68–84. pmid:29265416
  88. 88. Li C, Zhao Z, Zhou J, Liu Y, Wang H, Zhao X. Relationship between the TERT, TNIP1 and OBFC1 genetic polymorphisms and susceptibility to colorectal cancer in Chinese Han population. Oncotarget. 2017;8(34):56932–41. pmid:28915643
  89. 89. Hu Z-L, Li H-Y, Chang X, Li Y-Y, Liu C-H, Gao X-X, et al. Exosomes derived from stem cells as an emerging therapeutic strategy for intervertebral disc degeneration. World J Stem Cells. 2020;12(8):803–13. pmid:32952860
  90. 90. Li W, Zhang S, Wang D, Zhang H, Shi Q, Zhang Y, et al. Exosomes immunity strategy: a novel approach for ameliorating intervertebral disc degeneration. Front Cell Dev Biol. 2022;9:822149. pmid:35223870
  91. 91. Li Z, Wu Y, Tan G, Xu Z, Xue H. Exosomes and exosomal miRNAs: a new therapy for intervertebral disc degeneration. Front Pharmacol. 2022;13:992476. pmid:36160436
  92. 92. Lu L, Xu A, Gao F, Tian C, Wang H, Zhang J, et al. Mesenchymal stem cell-derived exosomes as a novel strategy for the treatment of intervertebral disc degeneration. Front Cell Dev Biol. 2022;9:770510. pmid:35141231
  93. 93. Widjaja G, Jalil AT, Budi HS, Abdelbasset WK, Efendi S, Suksatan W, et al. Mesenchymal stromal/stem cells and their exosomes application in the treatment of intervertebral disc disease: a promising frontier. Int Immunopharmacol. 2022;105:108537. pmid:35101851
  94. 94. Yang B, Yang X. Mesenchymal stem cell-derived exosomes are beneficial to suppressing inflammation and promoting autophagy in intervertebral disc degeneration. Folia Morphol (Warsz). 2024;83(1):102–12. pmid:36967623
  95. 95. Zhao X, Xu B, Duan W, Chang L, Tan R, Sun Z, et al. Insights into exosome in the intervertebral disc: emerging role for disc homeostasis and normal function. Int J Med Sci. 2022;19(11):1695–705. pmid:36237988
  96. 96. Zhao Y, Dong H, Xia Q, Wang Y, Zhu L, Hu Z, et al. A new strategy for intervertebral disc regeneration: the synergistic potential of mesenchymal stem cells and their extracellular vesicles with hydrogel scaffolds. Biomed Pharmacother. 2024;172:116238. pmid:38308965
  97. 97. Ambrosio L, Schol J, Ruiz-Fernandez C, Tamagawa S, Soma H, Tilotta V, et al. ISSLS PRIZE in Basic Science 2024: superiority of nucleus pulposus cell- versus mesenchymal stromal cell-derived extracellular vesicles in attenuating disc degeneration and alleviating pain. Eur Spine J. 2024;33(5):1713–27. pmid:38416190
  98. 98. Li L, Al-Jallad H, Sun A, Georgiopoulos M, Bokhari R, Ouellet J, et al. The proteomic landscape of extracellular vesicles derived from human intervertebral disc cells. JOR Spine. 2024;7(4):e70007. pmid:39507593
  99. 99. Yuan C, Song W, Jiang X, Wang Y, Li C, Yu W, et al. Adipose-derived stem cell-based optimization strategies for musculoskeletal regeneration: recent advances and perspectives. Stem Cell Res Ther. 2024;15(1):91. pmid:38539224
  100. 100. Karina K, Rosliana I, Rosadi I, Schwartz R, Sobariah S, Afini I, et al. Safety of technique and procedure of stromal vascular fraction therapy: from liposuction to cell administration. Scientifica (Cairo). 2020;2020:2863624. pmid:32695550
  101. 101. , Mahyudin F, Sigit Prakoeswa CR, Notobroto HB, Tinduh D, Ausrin R, et al. An update of current therapeutic approach for Intervertebral Disc Degeneration: a review article. Ann Med Surg (Lond). 2022;77:103619. pmid:35638079
  102. 102. Slack C. Ras signaling in aging and metabolic regulation. Nutr Healthy Aging. 2017;4(3):195–205. pmid:29276789
  103. 103. Tagney J. Sleep patterns related to rearing rats in enriched and impoverished environments. Brain Res. 1973;53(2):353–61. pmid:4350323
  104. 104. Williamson D, Gallagher P, Harber M, Hollon C, Trappe S. Mitogen-activated protein kinase (MAPK) pathway activation: effects of age and acute exercise on human skeletal muscle. J Physiol. 2003;547(Pt 3):977–87. pmid:12562918
  105. 105. Lufkin L, Samanta A, Baker D, Lufkin S, Schulze J, Ellis B, et al. Glis1 and oxaloacetate in nucleus pulposus stromal cell somatic reprogramming and survival. Front Mol Biosci. 2022;9:1009402. pmid:36406265
  106. 106. Debacq-Chainiaux F, Erusalimsky JD, Campisi J, Toussaint O. Protocols to detect senescence-associated beta-galactosidase (SA-betagal) activity, a biomarker of senescent cells in culture and in vivo. Nat Protoc. 2009;4(12):1798–806. pmid:20010931
  107. 107. Li M, Li R, Yang S, Yang D, Gao X, Sun J, et al. Exosomes derived from bone marrow mesenchymal stem cells prevent acidic pH-induced damage in human nucleus pulposus cells. Med Sci Monit. 2020;26:e922928. pmid:32436493
  108. 108. Théry C, Amigorena S, Raposo G, Clayton A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol. 2006;Chapter 3:Unit 3.22. pmid:18228490
  109. 109. Price JS, Waters JG, Darrah C, Pennington C, Edwards DR, Donell ST, et al. The role of chondrocyte senescence in osteoarthritis. Aging Cell. 2002;1(1):57–65. pmid:12882354
  110. 110. UniProt Consortium. UniProt: the Universal Protein Knowledgebase in 2023. Nucleic Acids Res. 2023;51(D1):D523–31. pmid:36408920
  111. 111. Keerthikumar S, Chisanga D, Ariyaratne D, Al Saffar H, Anand S, Zhao K, et al. ExoCarta: a web-based compendium of exosomal cargo. J Mol Biol. 2016;428(4):688–92. pmid:26434508
  112. 112. Zhang Z, Schäffer AA, Miller W, Madden TL, Lipman DJ, Koonin EV, et al. Protein sequence similarity searches using patterns as seeds. Nucleic Acids Res. 1998;26(17):3986–90. pmid:9705509
  113. 113. Li W, Jaroszewski L, Godzik A. Clustering of highly homologous sequences to reduce the size of large protein databases. Bioinformatics. 2001;17(3):282–3. pmid:11294794
  114. 114. Xu X, Yin F, Guo M, Gan G, Lin G, Wen C, et al. Quantitative proteomic analysis of exosomes from umbilical cord mesenchymal stem cells and rat bone marrow stem cells. Proteomics. 2023;23(1):e2200204. pmid:36408942
  115. 115. Koh J, Chen S, Zhu N, Yu F, Soltis PS, Soltis DE. Comparative proteomics of the recently and recurrently formed natural allopolyploid Tragopogon mirus (Asteraceae) and its parents. New Phytol. 2012;196(1):292–305. pmid:22861377
  116. 116. Tang D, Chen M, Huang X, Zhang G, Zeng L, Zhang G, et al. SRplot: a free online platform for data visualization and graphing. PLoS One. 2023;18(11):e0294236. pmid:37943830
  117. 117. Chen J, Bardes EE, Aronow BJ, Jegga AG. ToppGene Suite for gene list enrichment analysis and candidate gene prioritization. Nucleic Acids Res. 2009;37(Web Server issue):W305-11. pmid:19465376
  118. 118. Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607–13. pmid:30476243
  119. 119. Chitti SV, Gummadi S, Kang T, Shahi S, Marzan AL, Nedeva C, et al. Vesiclepedia 2024: an extracellular vesicles and extracellular particles repository. Nucleic Acids Res. 2024;52(D1):D1694–8. pmid:37953359
  120. 120. Kugeratski FG, Hodge K, Lilla S, McAndrews KM, Zhou X, Hwang RF, et al. Quantitative proteomics identifies the core proteome of exosomes with syntenin-1 as the highest abundant protein and a putative universal biomarker. Nat Cell Biol. 2021;23(6):631–41. pmid:34108659
  121. 121. Willms E, Johansson HJ, Mäger I, Lee Y, Blomberg KEM, Sadik M, et al. Cells release subpopulations of exosomes with distinct molecular and biological properties. Sci Rep. 2016;6:22519. pmid:26931825
  122. 122. Tombran-Tink J, Barnstable CJ. PEDF: a multifaceted neurotrophic factor. Nat Rev Neurosci. 2003;4(8):628–36. pmid:12894238
  123. 123. Lévesque J-P, Hendy J, Takamatsu Y, Simmons PJ, Bendall LJ. Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J Clin Invest. 2003;111(2):187–96. pmid:12531874
  124. 124. Sun Z, Liu B, Luo Z-J. The immune privilege of the intervertebral disc: implications for intervertebral disc degeneration treatment. Int J Med Sci. 2020;17(5):685–92. pmid:32210719
  125. 125. Yin C, Ackermann S, Ma Z, Mohanta SK, Zhang C, Li Y, et al. ApoE attenuates unresolvable inflammation by complex formation with activated C1q. Nat Med. 2019;25(3):496–506. pmid:30692699
  126. 126. Çetin G, Klafack S, Studencka-Turski M, Krüger E, Ebstein F. The ubiquitin-proteasome system in immune cells. Biomolecules. 2021;11(1):60. pmid:33466553
  127. 127. Reijnders MRF, Ansor NM, Kousi M, Yue WW, Tan PL, Clarkson K, et al. RAC1 missense mutations in developmental disorders with diverse phenotypes. Am J Hum Genet. 2017;101(3):466–77. pmid:28886345
  128. 128. Ridley AJ, Paterson HF, Johnston CL, Diekmann D, Hall A. The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. Cell. 1992;70(3):401–10. pmid:1643658
  129. 129. Zhao J, Mialki RK, Wei J, Coon TA, Zou C, Chen BB, et al. SCF E3 ligase F-box protein complex SCF(FBXL19) regulates cell migration by mediating Rac1 ubiquitination and degradation. FASEB J. 2013;27(7):2611–9. pmid:23512198
  130. 130. Chen H, Chédotal A, He Z, Goodman CS, Tessier-Lavigne M. Neuropilin-2, a novel member of the neuropilin family, is a high affinity receptor for the semaphorins Sema E and Sema IV but not Sema III. Neuron. 1997;19(3):547–59. pmid:9331348
  131. 131. Tóth EÁ, Turiák L, Visnovitz T, Cserép C, Mázló A, Sódar BW, et al. Formation of a protein corona on the surface of extracellular vesicles in blood plasma. J Extracell Vesicles. 2021;10(11):e12140. pmid:34520123
  132. 132. Nguyen TMD. Adiponectin: role in physiology and pathophysiology. Int J Prev Med. 2020;11:136. pmid:33088464
  133. 133. Doran AC, Yurdagul A Jr, Tabas I. Efferocytosis in health and disease. Nat Rev Immunol. 2020;20(4):254–67. pmid:31822793
  134. 134. Wang N, Jiang X, Zhang S, Zhu A, Yuan Y, Xu H, et al. Structural basis of human monocarboxylate transporter 1 inhibition by anti-cancer drug candidates. Cell. 2021;184(2):370-383.e13. pmid:33333023
  135. 135. Miron RJ, Estrin NE, Sculean A, Zhang Y. Understanding exosomes: Part 2-Emerging leaders in regenerative medicine. Periodontol 2000. 2024;94(1):257–414. pmid:38591622
  136. 136. Kodama J, Wilkinson KJ, Otsuru S. Nutrient metabolism of the nucleus pulposus: a literature review. N Am Spine Soc J. 2022;13:100191. pmid:36590450
  137. 137. Kohlmeier M. Chapter 6 - carbohydrates, alcohols, and organic acids. In: Kohlmeier M, editor. Nutrient metabolism. 2nd ed. San Diego: Academic Press; 2015. p. 187–242. https://doi.org/10.1016/B978-0-12-387784-0.00006-7
  138. 138. Huang Y-C, Urban JPG, Luk KDK. Intervertebral disc regeneration: do nutrients lead the way? Nat Rev Rheumatol. 2014;10(9):561–6. pmid:24914695
  139. 139. Yang D, Wang D, Shimer A, Shen FH, Li X, Yang X. Glutathione protects human nucleus pulposus cells from cell apoptosis and inhibition of matrix synthesis. Connect Tissue Res. 2014;55(2):132–9. pmid:24409809
  140. 140. Göran Ronquist K. Extracellular vesicles and energy metabolism. Clin Chim Acta. 2019;488:116–21. pmid:30395864
  141. 141. Read JA, Winter VJ, Eszes CM, Sessions RB, Brady RL. Structural basis for altered activity of M- and H-isozyme forms of human lactate dehydrogenase. Proteins. 2001;43(2):175–85. pmid:11276087
  142. 142. Colell A, Green DR, Ricci J-E. Novel roles for GAPDH in cell death and carcinogenesis. Cell Death Differ. 2009;16(12):1573–81. pmid:19779498
  143. 143. Wilde L, Roche M, Domingo-Vidal M, Tanson K, Philp N, Curry J, et al. Metabolic coupling and the Reverse Warburg Effect in cancer: implications for novel biomarker and anticancer agent development. Semin Oncol. 2017;44(3):198–203. pmid:29248131
  144. 144. Karner CM, Long F. Glucose metabolism in bone. Bone. 2018;115:2–7. pmid:28843700
  145. 145. Bochtler M, Ditzel L, Groll M, Hartmann C, Huber R. The proteasome. Annu Rev Biophys Biomol Struct. 1999;28:295–317. pmid:10410804
  146. 146. Pickering AM, Davies KJA. Degradation of damaged proteins: the main function of the 20S proteasome. Prog Mol Biol Transl Sci. 2012;109:227–48. pmid:22727423
  147. 147. Bec N, Bonhoure A, Henry L, Berry L, Larroque C, Coux O, et al. Proteasome 19S RP and translation preinitiation complexes are secreted within exosomes upon serum starvation. Traffic. 2019;20(7):516–36. pmid:31042005
  148. 148. Ben-Nissan G, Katzir N, Füzesi-Levi MG, Sharon M. Biology of the extracellular proteasome. Biomolecules. 2022;12(5):619. pmid:35625547
  149. 149. Dieudé M, Bell C, Turgeon J, Beillevaire D, Pomerleau L, Yang B, et al. The 20S proteasome core, active within apoptotic exosome-like vesicles, induces autoantibody production and accelerates rejection. Sci Transl Med. 2015;7(318):318ra200. pmid:26676607
  150. 150. Dixon CL, Sheller-Miller S, Saade GR, Fortunato SJ, Lai A, Palma C, et al. Amniotic fluid exosome proteomic profile exhibits unique pathways of term and preterm labor. Endocrinology. 2018;159(5):2229–40. pmid:29635386
  151. 151. García-Silva S, Benito-Martín A, Sánchez-Redondo S, Hernández-Barranco A, Ximénez-Embún P, Nogués L, et al. Use of extracellular vesicles from lymphatic drainage as surrogate markers of melanoma progression and BRAFV600E mutation. J Exp Med. 2019;216(5):1061–70. pmid:30975894
  152. 152. Guha D, Lorenz DR, Misra V, Chettimada S, Morgello S, Gabuzda D. Proteomic analysis of cerebrospinal fluid extracellular vesicles reveals synaptic injury, inflammation, and stress response markers in HIV patients with cognitive impairment. J Neuroinflammation. 2019;16(1):254. pmid:31805958
  153. 153. Haraszti RA, Didiot M-C, Sapp E, Leszyk J, Shaffer SA, Rockwell HE, et al. High-resolution proteomic and lipidomic analysis of exosomes and microvesicles from different cell sources. J Extracell Vesicles. 2016;5:32570. pmid:27863537
  154. 154. van Herwijnen MJC, Zonneveld MI, Goerdayal S, Nolte-’t Hoen ENM, Garssen J, Stahl B, et al. Comprehensive proteomic analysis of human milk-derived extracellular vesicles unveils a novel functional proteome distinct from other milk components. Mol Cell Proteomics. 2016;15(11):3412–23. pmid:27601599
  155. 155. Jimenez L, Yu H, McKenzie AJ, Franklin JL, Patton JG, Liu Q, et al. Quantitative proteomic analysis of small and large Extracellular Vesicles (EVs) reveals enrichment of adhesion proteins in small EVs. J Proteome Res. 2019;18(3):947–59. pmid:30608700
  156. 156. Prikryl P, Satrapova V, Frydlova J, Hruskova Z, Zima T, Tesar V, et al. Mass spectrometry-based proteomic exploration of the small urinary extracellular vesicles in ANCA-associated vasculitis in comparison with total urine. J Proteomics. 2021;233:104067. pmid:33307252
  157. 157. Sim SY, Choi YR, Lee JH, Lim JM, Lee S-E, Kim KP, et al. In-depth proteomic analysis of human bronchoalveolar lavage fluid toward the biomarker discovery for lung cancers. Proteomics Clin Appl. 2019;13(5):e1900028. pmid:31119868
  158. 158. Sixt SU, Dahlmann B. Extracellular, circulating proteasomes and ubiquitin - incidence and relevance. Biochim Biophys Acta. 2008;1782(12):817–23. pmid:18602990
  159. 159. Sun Y, Huo C, Qiao Z, Shang Z, Uzzaman A, Liu S, et al. Comparative proteomic analysis of exosomes and microvesicles in human saliva for lung cancer. J Proteome Res. 2018;17(3):1101–7. pmid:29397740
  160. 160. Yang C, Guo W-B, Zhang W-S, Bian J, Yang J-K, Zhou Q-Z, et al. Comprehensive proteomics analysis of exosomes derived from human seminal plasma. Andrology. 2017;5(5):1007–15. pmid:28914500
  161. 161. Zhou L, Zhao SZ, Koh SK, Chen L, Vaz C, Tanavde V, et al. In-depth analysis of the human tear proteome. J Proteomics. 2012;75(13):3877–85. pmid:22634083
  162. 162. Zhu Y, Chen X, Pan Q, Wang Y, Su S, Jiang C, et al. A comprehensive proteomics analysis reveals a secretory path- and status-dependent signature of exosomes released from tumor-associated macrophages. J Proteome Res. 2015;14(10):4319–31. pmid:26312558
  163. 163. Holtzman J, Lee H. Emerging role of extracellular vesicles in the respiratory system. Exp Mol Med. 2020;52(6):887–95. pmid:32541816
  164. 164. Zaborowski MP, Balaj L, Breakefield XO, Lai CP. Extracellular vesicles: composition, biological relevance, and methods of study. Bioscience. 2015;65(8):783–97. pmid:26955082
  165. 165. Bochmann I, Ebstein F, Lehmann A, Wohlschlaeger J, Sixt SU, Kloetzel P-M, et al. T lymphocytes export proteasomes by way of microparticles: a possible mechanism for generation of extracellular proteasomes. J Cell Mol Med. 2014;18(1):59–68. pmid:24304442
  166. 166. Vadas P, Pruzanski W, Stefanski E, Ellies LG, Aubin JE, Sos A, et al. Extracellular phospholipase A2 secretion is a common effector pathway of interleukin-1 and tumour necrosis factor action. Immunol Lett. 1991;28(3):187–93. pmid:1885215
  167. 167. Lai RC, Tan SS, Teh BJ, Sze SK, Arslan F, de Kleijn DP, et al. Proteolytic potential of the MSC exosome proteome: implications for an exosome-mediated delivery of therapeutic proteasome. Int J Proteomics. 2012;2012:971907. pmid:22852084
  168. 168. Liu Z-H, Sun Z, Wang H-Q, Ge J, Jiang T-S, Chen Y-F, et al. FasL expression on human nucleus pulposus cells contributes to the immune privilege of intervertebral disc by interacting with immunocytes. Int J Med Sci. 2013;10(8):1053–60. pmid:23801893
  169. 169. Takada T, Nishida K, Doita M, Kurosaka M. Fas ligand exists on intervertebral disc cells: a potential molecular mechanism for immune privilege of the disc. Spine (Phila Pa 1976). 2002;27(14):1526–30. pmid:12131712
  170. 170. Gu X, Chen A, Su Y, You M, Guo H, Tan S, et al. Extracellular vesicles: a new communication paradigm of complement in neurological diseases. Brain Res Bull. 2023;199:110667. pmid:37192717
  171. 171. Karasu E, Eisenhardt SU, Harant J, Huber-Lang M. Extracellular vesicles: packages sent with complement. Front Immunol. 2018;9:721. pmid:29696020
  172. 172. Guo S, Yan M, Li X, Zhang S, Liu Z, Li K, et al. Single-cell RNA-seq analysis reveals that immune cells induce human nucleus pulposus ossification and degeneration. Front Immunol. 2023;14:1224627. pmid:37638033
  173. 173. Zhang T-L, Chen W-K, Huang X-P, Zheng B-W, Wu P-F, Zheng B-Y, et al. Single-cell RNA sequencing reveals the MIF/ACKR3 receptor-ligand interaction between neutrophils and nucleus pulposus cells in intervertebral disc degeneration. Transl Res. 2024;272:1–18. pmid:38823438
  174. 174. Marki A, Ley K. The expanding family of neutrophil-derived extracellular vesicles. Immunol Rev. 2022;312(1):52–60. pmid:35665941
  175. 175. Lenzini S, Bargi R, Chung G, Shin J-W. Matrix mechanics and water permeation regulate extracellular vesicle transport. Nat Nanotechnol. 2020;15(3):217–23. pmid:32066904
  176. 176. Blanter M, Gouwy M, Struyf S. Studying neutrophil function in vitro: cell models and environmental factors. J Inflamm Res. 2021;14:141–62. pmid:33505167
  177. 177. Heggli I, Teixeira GQ, Iatridis JC, Neidlinger-Wilke C, Dudli S. The role of the complement system in disc degeneration and Modic changes. JOR Spine. 2024;7(1):e1312. pmid:38312949
  178. 178. Kraus P, Li K, Sipes D, Varden L, Yerden R, Henderson A, et al. Single-cell phenotyping of complex heterogeneous tissue. In: Santra TS, Tseng F-G, editors. Handbook of single cell technologies. Singapore: Springer Singapore; 2019. p. 1–17. https://doi.org/10.1007/978-981-10-4857-9_16-1
  179. 179. Hassanpour M, Rezabakhsh A, Rezaie J, Nouri M, Rahbarghazi R. Exosomal cargos modulate autophagy in recipient cells via different signaling pathways. Cell Biosci. 2020;10:92. pmid:32765827
  180. 180. Tan F, Li X, Wang Z, Li J, Shahzad K, Zheng J. Clinical applications of stem cell-derived exosomes. Signal Transduct Target Ther. 2024;9(1):17. pmid:38212307
  181. 181. Urbanelli L, Magini A, Buratta S, Brozzi A, Sagini K, Polchi A, et al. Signaling pathways in exosomes biogenesis, secretion and fate. Genes (Basel). 2013;4(2):152–70. pmid:24705158
  182. 182. Verweij FJ, Middeldorp JM, Pegtel DM. Intracellular signaling controlled by the endosomal-exosomal pathway. Commun Integr Biol. 2012;5(1):88–93. pmid:22482020
  183. 183. Strassburg S, Hodson NW, Hill PI, Richardson SM, Hoyland JA. Bi-directional exchange of membrane components occurs during co-culture of mesenchymal stem cells and nucleus pulposus cells. PLoS One. 2012;7(3):e33739. pmid:22438989
  184. 184. Cheng X, Zhang G, Zhang L, Hu Y, Zhang K, Sun X, et al. Mesenchymal stem cells deliver exogenous miR-21 via exosomes to inhibit nucleus pulposus cell apoptosis and reduce intervertebral disc degeneration. J Cell Mol Med. 2018;22(1):261–76. pmid:28805297
  185. 185. Sun Z, Liu B, Liu Z-H, Song W, Wang D, Chen B-Y, et al. Notochordal-cell-derived exosomes induced by compressive load inhibit angiogenesis via the miR-140-5p/Wnt/β-Catenin axis. Mol Ther Nucleic Acids. 2020;22:1092–106. pmid:33294295
  186. 186. Ramos AP, Sebinelli HG, Ciancaglini P, Rosato N, Mebarek S, Buchet R, et al. The functional role of soluble proteins acquired by extracellular vesicles. J Extracell Biol. 2022;1(1):e34. pmid:38938684
  187. 187. Borregaard N, Sørensen OE, Theilgaard-Mönch K. Neutrophil granules: a library of innate immunity proteins. Trends Immunol. 2007;28(8):340–5. pmid:17627888
  188. 188. Saint-Pol J, Gosselet F, Duban-Deweer S, Pottiez G, Karamanos Y. Targeting and crossing the blood-brain barrier with extracellular vesicles. Cells. 2020;9(4):851. pmid:32244730
  189. 189. Brückner K, Pasquale EB, Klein R. Tyrosine phosphorylation of transmembrane ligands for Eph receptors. Science. 1997;275(5306):1640–3. pmid:9054357
  190. 190. Taylor H, Campbell J, Nobes CD. Ephs and ephrins. Curr Biol. 2017;27(3):R90–5. pmid:28171762
  191. 191. Arvanitis D, Davy A. Eph/ephrin signaling: networks. Genes Dev. 2008;22(4):416–29. pmid:18281458
  192. 192. Kania A, Klein R. Mechanisms of ephrin-Eph signalling in development, physiology and disease. Nat Rev Mol Cell Biol. 2016;17(4):240–56. pmid:26790531
  193. 193. Lisabeth EM, Falivelli G, Pasquale EB. Eph receptor signaling and ephrins. Cold Spring Harb Perspect Biol. 2013;5(9):a009159. pmid:24003208
  194. 194. Binns KL, Taylor PP, Sicheri F, Pawson T, Holland SJ. Phosphorylation of tyrosine residues in the kinase domain and juxtamembrane region regulates the biological and catalytic activities of Eph receptors. Mol Cell Biol. 2000;20(13):4791–805. pmid:10848605
  195. 195. Pasquale EB. Exosomes expand the sphere of influence of Eph receptors and ephrins. J Cell Biol. 2016;214(1):5–7. pmid:27354377
  196. 196. Wallingford JB, Fraser SE, Harland RM. Convergent extension: the molecular control of polarized cell movement during embryonic development. Dev Cell. 2002;2(6):695–706. pmid:12062082
  197. 197. Arthur A, Gronthos S. Eph-ephrin signaling mediates cross-talk within the bone microenvironment. Front Cell Dev Biol. 2021;9:598612. pmid:33634116
  198. 198. Gong J, Körner R, Gaitanos L, Klein R. Exosomes mediate cell contact-independent ephrin-Eph signaling during axon guidance. J Cell Biol. 2016;214(1):35–44. pmid:27354374
  199. 199. Marston DJ, Dickinson S, Nobes CD. Rac-dependent trans-endocytosis of ephrinBs regulates Eph-ephrin contact repulsion. Nat Cell Biol. 2003;5(10):879–88. pmid:12973357
  200. 200. Stewen J, Kruse K, Godoi-Filip AT, , Jeong H-W, Adams S, et al. Eph-ephrin signaling couples endothelial cell sorting and arterial specification. Nat Commun. 2024;15(1):2539. pmid:38570531
  201. 201. van der Pol E, Böing AN, Harrison P, Sturk A, Nieuwland R. Classification, functions, and clinical relevance of extracellular vesicles. Pharmacol Rev. 2012;64(3):676–705. pmid:22722893
  202. 202. Yáñez-Mó M, Siljander PR-M, Andreu Z, Zavec AB, Borràs FE, Buzas EI, et al. Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles. 2015;4:27066. pmid:25979354
  203. 203. Sahai E, Marshall CJ. RHO-GTPases and cancer. Nat Rev Cancer. 2002;2(2):133–42. pmid:12635176
  204. 204. Sexton RE, Mpilla G, Kim S, Philip PA, Azmi AS. Ras and exosome signaling. Semin Cancer Biol. 2019;54:131–7. pmid:30769101
  205. 205. Karar J, Maity A. PI3K/AKT/mTOR pathway in angiogenesis. Front Mol Neurosci. 2011;4:51. pmid:22144946
  206. 206. Popović L, Wintgens JP, Wu Y, Brankatschk B, Menninger S, Degenhart C, et al. Profiling of ERBB receptors and downstream pathways reveals selectivity and hidden properties of ERBB4 antagonists. iScience. 2024;27(2):108839. pmid:38303712
  207. 207. Ouyang Z-H, Wang W-J, Yan Y-G, Wang B, Lv G-H. The PI3K/Akt pathway: a critical player in intervertebral disc degeneration. Oncotarget. 2017;8(34):57870–81. pmid:28915718
  208. 208. Cuesta C, Arévalo-Alameda C, Castellano E. The importance of being PI3K in the RAS signaling network. Genes (Basel). 2021;12(7):1094. pmid:34356110
  209. 209. Lai H-C, Chang Q-Y, Hsieh C-L. Signal transduction pathways of acupuncture for treating some nervous system diseases. Evid Based Complement Alternat Med. 2019;2019:2909632. pmid:31379957
  210. 210. Shi Z-W, Zhu L, Song Z-R, Liu T-J, Hao D-J. Roles of p38 MAPK signalling in intervertebral disc degeneration. Cell Prolif. 2023;56(8):e13438. pmid:36872558
  211. 211. Yang SI, Yuan Y, Jiao S, Luo QI, Yu J. Calcitonin gene-related peptide protects rats from cerebral ischemia/reperfusion injury via a mechanism of action in the MAPK pathway. Biomed Rep. 2016;4(6):699–703. pmid:27284409
  212. 212. Zhang H-J, Liao H-Y, Bai D-Y, Wang Z-Q, Xie X-W. MAPK /ERK signaling pathway: a potential target for the treatment of intervertebral disc degeneration. Biomed Pharmacother. 2021;143:112170. pmid:34536759
  213. 213. Jopling C, Boue S, Izpisua Belmonte JC. Dedifferentiation, transdifferentiation and reprogramming: three routes to regeneration. Nat Rev Mol Cell Biol. 2011;12(2):79–89. pmid:21252997
  214. 214. Kamao H, Mandai M, Okamoto S, Sakai N, Suga A, Sugita S, et al. Characterization of human induced pluripotent stem cell-derived retinal pigment epithelium cell sheets aiming for clinical application. Stem Cell Rep. 2014;2(2):205–18. pmid:24527394
  215. 215. Wang H, Yang Y, Liu J, Qian L. Direct cell reprogramming: approaches, mechanisms and progress. Nat Rev Mol Cell Biol. 2021;22(6):410–24. pmid:33619373
  216. 216. Xia K, Gong Z, Zhu J, Yu W, Wang Y, Wang J, et al. Differentiation of pluripotent stem cells into nucleus pulposus progenitor cells for intervertebral disc regeneration. Curr Stem Cell Res Ther. 2019;14(1):57–64. pmid:30227822
  217. 217. Chen TS, Lai RC, Lee MM, Choo ABH, Lee CN, Lim SK. Mesenchymal stem cell secretes microparticles enriched in pre-microRNAs. Nucleic Acids Res. 2010;38(1):215–24. pmid:19850715
  218. 218. Luo L, Jian X, Sun H, Qin J, Wang Y, Zhang J, et al. Cartilage endplate stem cells inhibit intervertebral disc degeneration by releasing exosomes to nucleus pulposus cells to activate Akt/autophagy. Stem Cells. 2021;39(4):467–81. pmid:33459443
  219. 219. Zhang Q-C, Hu S-Q, Hu A-N, Zhang T-W, Jiang L-B, Li X-L. Autophagy-activated nucleus pulposus cells deliver exosomal miR-27a to prevent extracellular matrix degradation by targeting MMP-13. J Orthop Res. 2021;39(9):1921–32. pmid:33038032
  220. 220. Antoniou J, Steffen T, Nelson F, Winterbottom N, Hollander AP, Poole RA, et al. The human lumbar intervertebral disc: evidence for changes in the biosynthesis and denaturation of the extracellular matrix with growth, maturation, ageing, and degeneration. J Clin Invest. 1996;98(4):996–1003. pmid:8770872
  221. 221. Kumari R, Jat P. Mechanisms of cellular senescence: cell cycle arrest and senescence associated secretory phenotype. Front Cell Dev Biol. 2021;9:645593. pmid:33855023
  222. 222. Lama P, Le Maitre CL, Harding IJ, Dolan P, Adams MA. Nerves and blood vessels in degenerated intervertebral discs are confined to physically disrupted tissue. J Anat. 2018;233(1):86–97. pmid:29708266
  223. 223. Le Maitre CL, Freemont AJ, Hoyland JA. Localization of degradative enzymes and their inhibitors in the degenerate human intervertebral disc. J Pathol. 2004;204(1):47–54. pmid:15307137
  224. 224. Molinos M, Cunha C, Almeida CR, Gonçalves RM, Pereira P, Silva PS, et al. Age-correlated phenotypic alterations in cells isolated from human degenerated intervertebral discs with contained hernias. Spine (Phila Pa 1976). 2018;43(5):E274–84. pmid:28678109
  225. 225. Molinos M, Almeida CR, Caldeira J, Cunha C, Gonçalves RM, Barbosa MA. Inflammation in intervertebral disc degeneration and regeneration. J R Soc Interface. 2015;12(104):20141191. pmid:25673296
  226. 226. Singh K, Masuda K, Thonar EJ-MA, An HS, Cs-Szabo G. Age-related changes in the extracellular matrix of nucleus pulposus and anulus fibrosus of human intervertebral disc. Spine (Phila Pa 1976). 2009;34(1):10–6. pmid:19127156
  227. 227. Bouvard D, Brakebusch C, Gustafsson E, Aszódi A, Bengtsson T, Berna A, et al. Functional consequences of integrin gene mutations in mice. Circ Res. 2001;89(3):211–23. pmid:11485971
  228. 228. ffrench-Constant C, Colognato H. Integrins: versatile integrators of extracellular signals. Trends Cell Biol. 2004;14(12):678–86. pmid:15564044
  229. 229. Juliano RL, Reddig P, Alahari S, Edin M, Howe A, Aplin A. Integrin regulation of cell signalling and motility. Biochem Soc Trans. 2004;32(Pt3):443–6. pmid:15157156
  230. 230. Krishnamurthy M, Li J, Fellows GF, Rosenberg L, Goodyer CG, Wang R. Integrin {alpha}3, but not {beta}1, regulates islet cell survival and function via PI3K/Akt signaling pathways. Endocrinology. 2011;152(2):424–35. pmid:21177833
  231. 231. Labat-Robert J. Cell-Matrix interactions, the role of fibronectin and integrins. A survey. Pathol Biol (Paris). 2012;60(1):15–9. pmid:22265966
  232. 232. Miyamoto S, Katz BZ, Lafrenie RM, Yamada KM. Fibronectin and integrins in cell adhesion, signaling, and morphogenesis. Ann N Y Acad Sci. 1998;857:119–29. pmid:9917837
  233. 233. Chanda D, Otoupalova E, Hough KP, Locy ML, Bernard K, Deshane JS, et al. Fibronectin on the surface of extracellular vesicles mediates fibroblast invasion. Am J Respir Cell Mol Biol. 2019;60(3):279–88. pmid:30321056
  234. 234. Laterra J, Silbert JE, Culp LA. Cell surface heparan sulfate mediates some adhesive responses to glycosaminoglycan-binding matrices, including fibronectin. J Cell Biol. 1983;96(1):112–23. pmid:6219115
  235. 235. Purushothaman A, Bandari SK, Liu J, Mobley JA, Brown EE, Sanderson RD. Fibronectin on the surface of myeloma cell-derived exosomes mediates exosome-cell interactions. J Biol Chem. 2016;291(4):1652–63. pmid:26601950
  236. 236. Chang AC, Uto K, Homma K, Nakanishi J. Viscoelastically tunable substrates elucidate the interface-relaxation-dependent adhesion and assembly behaviors of epithelial cells. Biomaterials. 2021;274:120861. pmid:33991949
  237. 237. Chen MB, Lamar JM, Li R, Hynes RO, Kamm RD. Elucidation of the roles of tumor integrin β1 in the extravasation stage of the metastasis cascade. Cancer Res. 2016;76(9):2513–24. pmid:26988988
  238. 238. He J, Zeng F, Jin XI, Liang L, Gao M, Li W, et al. YWHAH activates the HMGA1/PI3K/AKT/mTOR signaling pathway by positively regulating Fra-1 to affect the proliferation of gastric cancer cells. Oncol Res. 2023;31(4):615–30. pmid:37415737
  239. 239. Kryeziu K, Bruun J, Guren TK, Sveen A, Lothe RA. Combination therapies with HSP90 inhibitors against colorectal cancer. Biochim Biophys Acta Rev Cancer. 2019;1871(2):240–7. pmid:30708039
  240. 240. Redlak MJ, Miller TA. Targeting PI3K/Akt/HSP90 signaling sensitizes gastric cancer cells to deoxycholate-induced apoptosis. Dig Dis Sci. 2011;56(2):323–9. pmid:20585984
  241. 241. Sun Z, Yang J, Li H, Wang C, Fletcher C, Li J, et al. Progress in the research of nanomaterial-based exosome bioanalysis and exosome-based nanomaterials tumor therapy. Biomaterials. 2021;274:120873. pmid:33989972
  242. 242. Wang C, Wang M, Xu T, Zhang X, Lin C, Gao W, et al. Engineering bioactive self-healing antibacterial exosomes hydrogel for promoting chronic diabetic wound healing and complete skin regeneration. Theranostics. 2019;9(1):65–76. pmid:30662554
  243. 243. Wei H, Zhang Y, Jia Y, Chen X, Niu T, Chatterjee A, et al. Heat shock protein 90: biological functions, diseases, and therapeutic targets. MedComm (2020). 2024;5(2):e470. pmid:38283176
  244. 244. Wu C, You J, Fu J, Wang X, Zhang Y. Phosphatidylinositol 3-kinase/akt mediates integrin signaling to control RNA polymerase I transcriptional activity. Mol Cell Biol. 2016;36(10):1555–68. pmid:26976639
  245. 245. Yamada Y, Hozumi K, Katagiri F, Kikkawa Y, Nomizu M. Laminin-111-derived peptide-hyaluronate hydrogels as a synthetic basement membrane. Biomaterials. 2013;34(28):6539–47. pmid:23764113
  246. 246. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell. 2002;110(6):673–87. pmid:12297042
  247. 247. Pozzi A, Zent R. Integrins: sensors of extracellular matrix and modulators of cell function. Nephron Exp Nephrol. 2003;94(3):e77-84. pmid:12902617
  248. 248. Greg Anderson D, Li X, Tannoury T, Beck G, Balian G. A fibronectin fragment stimulates intervertebral disc degeneration in vivo. Spine (Phila Pa 1976). 2003;28(20):2338–45. pmid:14560080
  249. 249. Oegema TR Jr, Johnson SL, Aguiar DJ, Ogilvie JW. Fibronectin and its fragments increase with degeneration in the human intervertebral disc. Spine (Phila Pa 1976). 2000;25(21):2742–7. pmid:11064518
  250. 250. Anderson DG, Li X, Balian G. A fibronectin fragment alters the metabolism by rabbit intervertebral disc cells in vitro. Spine (Phila Pa 1976). 2005;30(11):1242–6. pmid:15928546
  251. 251. Homandberg GA, Hui F, Wen C, Purple C, Bewsey K, Koepp H, et al. Fibronectin-fragment-induced cartilage chondrolysis is associated with release of catabolic cytokines. Biochem J. 1997;321 ( Pt 3)(Pt 3):751–7. pmid:9032463
  252. 252. Schmidli MR, Sadowska A, Cvitas I, Gantenbein B, Lischer HEL, Forterre S, et al. Fibronectin fragments and inflammation during canine intervertebral disc disease. Front Vet Sci. 2020;7:547644. pmid:33304936
  253. 253. Stanton H, Ung L, Fosang AJ. The 45 kDa collagen-binding fragment of fibronectin induces matrix metalloproteinase-13 synthesis by chondrocytes and aggrecan degradation by aggrecanases. Biochem J. 2002;364(Pt 1):181–90. pmid:11988091
  254. 254. Groulx J-F, Gagné D, Benoit YD, Martel D, Basora N, Beaulieu J-F. Collagen VI is a basement membrane component that regulates epithelial cell-fibronectin interactions. Matrix Biol. 2011;30(3):195–206. pmid:21406227
  255. 255. Kadler KE, Hill A, Canty-Laird EG. Collagen fibrillogenesis: fibronectin, integrins, and minor collagens as organizers and nucleators. Curr Opin Cell Biol. 2008;20(5):495–501. pmid:18640274
  256. 256. McDonald JA, Kelley DG, Broekelmann TJ. Role of fibronectin in collagen deposition: Fab’ to the gelatin-binding domain of fibronectin inhibits both fibronectin and collagen organization in fibroblast extracellular matrix. J Cell Biol. 1982;92(2):485–92. pmid:7061591
  257. 257. Cescon M, Gattazzo F, Chen P, Bonaldo P. Collagen VI at a glance. J Cell Sci. 2015;128(19):3525–31. pmid:26377767
  258. 258. Bushby KMD, Collins J, Hicks D. Collagen type VI myopathies. In: Halper J, editor. Progress in heritable soft connective tissue diseases. Dordrecht: Springer Netherlands; 2014. p. 185–199. https://doi.org/10.1007/978-94-007-7893-1_12
  259. 259. Smeriglio P, Lee J, Bhutani N. Soluble Collagen VI treatment enhances mesenchymal stem cells expansion for engineering cartilage. Bioeng Transl Med. 2017;2(3):278–84. pmid:29313037
  260. 260. Cescon M, Chen P, Castagnaro S, Gregorio I, Bonaldo P. Lack of collagen VI promotes neurodegeneration by impairing autophagy and inducing apoptosis during aging. Aging (Albany NY). 2016;8(5):1083–101. pmid:27060109
  261. 261. Lamandé SR, Bateman JF. Collagen VI disorders: Insights on form and function in the extracellular matrix and beyond. Matrix Biol. 2018;71–72:348–67. pmid:29277723
  262. 262. Smeriglio P, Dhulipala L, Lai JH, Goodman SB, Dragoo JL, Smith RL, et al. Collagen VI enhances cartilage tissue generation by stimulating chondrocyte proliferation. Tissue Eng Part A. 2015;21(3–4):840–9. pmid:25257043